<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="twitter:card" content="summary"/><meta name="twitter:site" content="@researchsquare"/><meta name="twitter:creator" content="@researchsquare"/><meta property="og:url" content="https://www.researchsquare.com"/><meta property="og:type" content="website"/><meta property="og:image:alt" content="Research Square"/><meta property="og:image:width" content="1280"/><meta property="og:image:height" content="720"/><meta property="og:locale" content="en_US"/><title>Neuroimaging of affective symptoms in Lewy body dementia: A systematic review | Research Square</title><meta name="robots" content="index,follow"/><meta property="og:title" content="Neuroimaging of affective symptoms in Lewy body dementia: A systematic review"/><meta property="og:description" content="BackgroundAffective symptoms, such as depression, anxiety and apathy, are highly prevalent in Lewy body diseases (LBDs), including both Parkinson&amp;rsquo;s disease and dementia with Lewy bodies. Despite their association with cognitive decline, their underlying neuropathological mechani..."/><meta property="og:image" content=""/><meta name="viewport" content="width=device-width, initial-scale=1"/><meta name="apple-mobile-web-app-title" content="Research Square"/><meta name="application-name" content="Research Square"/><link rel="shortcut icon" type="image/x-icon" href="/static/favicons/favicon.ico"/><link rel="apple-touch-icon" sizes="180x180" href="/static/favicons/apple-touch-icon.png"/><link rel="icon" type="image/png" sizes="32x32" href="/static/favicons/favicon-32x32.png"/><link rel="icon" type="image/png" sizes="16x16" href="/static/favicons/favicon-16x16.png"/><link rel="manifest" href="/static/favicons/site.webmanifest"/><link rel="mask-icon" href="/static/favicons/safari-pinned-tab.svg" color="#244261"/><meta name="msapplication-config" content="/static/favicons/browserconfig.xml"/><meta name="msapplication-TileColor" content="#ffffff"/><meta name="theme-color" content="#ffffff"/><link rel="preconnect" href="https://fonts.gstatic.com/" crossorigin="anonymous"/><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"/><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="anonymous"/><link rel="preconnect" href="https://app.snipcart.com"/><link rel="preconnect" href="https://cdn.snipcart.com"/><link rel="canonical" href="&#x27;https://www.researchsquare.com/article/rs-7472898/v1"/><meta name="description" content="BackgroundAffective symptoms, such as depression, anxiety and apathy, are highly prevalent in Lewy body diseases (LBDs), including both Parkinson&amp;rsquo;s disease and dementia with Lewy bodies. Despite their association with cognitive decline, their underlying neuropathological mechani..."/><meta property="og:title" content="Neuroimaging of affective symptoms in Lewy body dementia: A systematic review"/><meta property="og:description" content="BackgroundAffective symptoms, such as depression, anxiety and apathy, are highly prevalent in Lewy body diseases (LBDs), including both Parkinson&amp;rsquo;s disease and dementia with Lewy bodies. Despite their association with cognitive decline, their underlying neuropathological mechani..."/><meta property="og:url" content="&#x27;https://www.researchsquare.com/article/rs-7472898/v1"/><meta property="og:type" content="article"/><meta name="twitter:title" content="Neuroimaging of affective symptoms in Lewy body dementia: A systematic review"/><meta name="twitter:description" content="BackgroundAffective symptoms, such as depression, anxiety and apathy, are highly prevalent in Lewy body diseases (LBDs), including both Parkinson&amp;rsquo;s disease and dementia with Lewy bodies. Despite their association with cognitive decline, their underlying neuropathological mechani..."/><meta name="citation_publication_date" content="2025-09-01"/><meta property="citation_author" content="Naomi Mullis"/><meta property="citation_author" content="Laura M Wright"/><meta name="citation_title" content="Neuroimaging of affective symptoms in Lewy body dementia: A systematic review"/><meta name="citation_doi" content="10.21203/rs.3.rs-7472898/v1"/><meta name="citation_pdf_url" content="https://www.researchsquare.com/article/rs-7472898/latest.pdf"/><script async="">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R');</script><meta name="next-head-count" content="47"/><script async="" src="https://polyfill-fastly.io/v3/polyfill.min.js?flags=gated&amp;features=String.prototype.startsWith%2CString.prototype.endsWith%2CArray.prototype.forEach%2CSet%2CArray.prototype.includes%2CString.prototype.includes%2CArray.prototype.find%2CMap%2CObject.values"></script><link rel="prefetch stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.11.2/css/all.min.css" integrity="sha256-+N4/V/SbAFiW1MPBCXnfnP9QSN3+Keu+NlB+0ev/YKQ=" crossorigin="anonymous"/><link rel="preconnect" href="https://app.snipcart.com"/><link rel="preconnect" href="https://cdn.snipcart.com"/><link rel="prefetch stylesheet" href="https://cdn.snipcart.com/themes/v3.3.0/default/snipcart.css"/><script async="" src="https://cdn.snipcart.com/themes/v3.3.0/default/snipcart.js"></script><link data-next-font="" rel="preconnect" href="/" crossorigin="anonymous"/><link rel="preload" href="/_next/static/css/097af2fce36b4545.css" as="style"/><link rel="stylesheet" href="/_next/static/css/097af2fce36b4545.css" data-n-g=""/><link rel="preload" href="/_next/static/css/74fc351921f6806e.css" as="style"/><link rel="stylesheet" href="/_next/static/css/74fc351921f6806e.css" data-n-p=""/><link rel="preload" href="/_next/static/css/5eb7067aaea39ce0.css" as="style"/><link rel="stylesheet" href="/_next/static/css/5eb7067aaea39ce0.css"/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-42372ed130431b0a.js"></script><script defer="" src="/_next/static/chunks/2b7b2d2a-fb8e248e4f64c09b.js"></script><script defer="" src="/_next/static/chunks/6086-d8b3d1ee0298789b.js"></script><script defer="" src="/_next/static/chunks/8719.7a9257edd8ce0cc0.js"></script><script src="/_next/static/chunks/webpack-0bfccabd01ff3222.js" defer=""></script><script src="/_next/static/chunks/framework-88f2b98ffb47976f.js" defer=""></script><script src="/_next/static/chunks/main-e365b9365853811f.js" defer=""></script><script src="/_next/static/chunks/pages/_app-28c7c0855f57abf7.js" defer=""></script><script src="/_next/static/chunks/75fc9c18-a8c9805be41684e2.js" defer=""></script><script src="/_next/static/chunks/d6e1aeb5-d41cf1c71f0906fb.js" defer=""></script><script src="/_next/static/chunks/2981-d6d616b40ecc010b.js" defer=""></script><script src="/_next/static/chunks/7206-4b589a2cfeb5b511.js" defer=""></script><script src="/_next/static/chunks/724-4454ccdce88563f0.js" defer=""></script><script src="/_next/static/chunks/7915-505fa2b3a25928a0.js" defer=""></script><script src="/_next/static/chunks/4197-895c5fe4fad6142f.js" defer=""></script><script src="/_next/static/chunks/722-3bf0cafff23e180b.js" defer=""></script><script src="/_next/static/chunks/5598-12e41c77dcb43113.js" defer=""></script><script src="/_next/static/chunks/7947-4632d0176d1c053d.js" defer=""></script><script src="/_next/static/chunks/2266-d9f85647fec60448.js" defer=""></script><script src="/_next/static/chunks/1265-58d1a9f1e6177740.js" defer=""></script><script src="/_next/static/chunks/pages/article/%5Bidentity%5D/%5B%5B...version%5D%5D-17b9d7f3c19e0296.js" defer=""></script><script src="/_next/static/pX42vdylg-PjXqQvD3Sgd/_buildManifest.js" defer=""></script><script src="/_next/static/pX42vdylg-PjXqQvD3Sgd/_ssgManifest.js" defer=""></script><style id="__jsx-1810699180">.jsx-1810699180:export{white:#FFFFFF;grey10:#FAFAFA;grey20:#F2F2F3;grey30:#E5E6E8;grey40:#CCCFD2;grey50:#B2B7BC;grey60:#999FA6;grey65:#7F8790;grey70:#66707A;grey80:#33404E;grey90:#192837;black:#001122;g1:#F3FBF6;g2:#3AAE74;g3:#319767;g4:#268455;g5:#20734D;g6:#63b91a;b1:#F2F6FB;b2:#186EC4;b3:#175089;b4:#1B4064;b5:#15324E;y1:#FFFCEB;y2:#EBCC5F;orange:#E9BE5C;orange-2:#FB8C00;orange-3:#EF6C00;}#search-button.jsx-1810699180{pointer-events:auto;}#search-input.jsx-1810699180{font-size:14px;padding-top:1rem;padding-bottom:1rem;-webkit-letter-spacing:0.3px;-moz-letter-spacing:0.3px;-ms-letter-spacing:0.3px;letter-spacing:0.3px;}#search-input.jsx-1810699180::-webkit-input-placeholder{color:#66707A;}#search-input.jsx-1810699180::-moz-placeholder{color:#66707A;}#search-input.jsx-1810699180:-ms-input-placeholder{color:#66707A;}#search-input.jsx-1810699180::placeholder{color:#66707A;}#search-button.jsx-1810699180{padding-bottom:0.3rem;}#search-button.jsx-1810699180:disabled{pointer-events:none;}#search-icon.jsx-1810699180{color:#CCCFD2;}#search-icon.jsx-1810699180:hover{color:#66707A;}#search-spinner.jsx-1810699180{color:#66707A;}</style><style id="__jsx-3772613807">.lightbox-wrapper .yarl__slide{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-flex-direction:column;-ms-flex-direction:column;flex-direction:column;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;-webkit-box-pack:center;-webkit-justify-content:center;-ms-flex-pack:center;justify-content:center;}.lightbox-wrapper .yarl__slide_wrapper{max-height:80%;overflow-y:auto;}.lightbox-wrapper .yarl__slide_description_container{width:100%;max-height:20%;overflow-y:auto;background:rgba(0,0,0,0.85);color:white;padding:1rem;box-sizing:border-box;}.lightbox-wrapper .yarl__slide_description,.lightbox-wrapper .yarl__slide_description *{-webkit-user-select:text !important;-moz-user-select:text !important;-ms-user-select:text !important;user-select:text !important;pointer-events:auto !important;}</style></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K279D39R" height="0" width="0" style="display:none;visibility:hidden" /></noscript><div id="__next"><div class="no-scroll"><div class="original-css"><nav class="rs-navbar false
                    false
                " role="navigation" aria-label="navigation"><div class="rs-container rs-ph"><div class="left"><div class="hamburger hamburger--squeeze false false" role="navigation"><div class="hamburger-box"><div class="hamburger-inner"></div></div></div><a href="/"><img class="logo-rs" src="/static/img/logos/logo-rs.svg" alt="Research Square"/></a><form class="jsx-1810699180 b-pl-10"><div class="jsx-1810699180 control has-icons-right lg:tw-w-96 md:tw-w-52"><input type="text" placeholder="Search preprints" id="search-input" class="jsx-1810699180 input"/><button disabled="" id="search-button" type="submit" class="jsx-1810699180 icon is-small is-right rounded-r-md"><i id="search-icon" class="jsx-1810699180 fas fa-search"></i></button></div></form></div><div class="right"><div class="nav-link"><h6>Browse</h6><i class="fas fa-caret-down"></i><div class="nav-dropdown"><div class=""><a href="/browse"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">Preprints</h6></div></a></div><div class=""><a href="/journals"><div class="nav-link  "><h6 class="align" style="text-wrap:initial"><span class="is-italic">In Review </span>Journals</h6></div></a></div><div class=""><a href="/coronavirus"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">COVID-19 Preprints</h6></div></a></div><div class=""><a href="/browse?articleType=Video"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">AJE Video Bytes</h6></div></a></div><div class="b-mb-15"></div></div></div><div class="nav-link"><h6>Research Tools</h6><i class="fas fa-caret-down"></i><div class="nav-dropdown"><div class=""><a href="/researchers/promotion"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">Research Promotion</h6></div></a></div><div class=""><a href="/researchers/editing"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">AJE Professional Editing</h6></div></a></div><div class=""><a href="/researchers/rubriq"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">AJE Rubriq</h6></div></a></div><div class="b-mb-15"></div></div></div><div class="nav-link"><h6>About</h6><i class="fas fa-caret-down"></i><div class="nav-dropdown"><div class=""><a href="/researchers/preprints"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">Preprint Platform</h6></div></a></div><div class=""><a href="/researchers/in-review"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">In Review</h6></div></a></div><div class=""><a href="/legal/editorial"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">Editorial Policies</h6></div></a></div><div class=""><a href="/research-quality-evaluation"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">Research Quality Evaluation </h6></div></a></div><div class=""><a href="/about"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">Our Team</h6></div></a></div><div class=""><a href="/advisory-board"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">Advisory Board</h6></div></a></div><div class=""><a href="https://support.researchsquare.com" target="_blank" rel="noopener noreferrer" data-track="click_contact_us_button" data-track-context="Help Centre, Contact us link clicked from arrow links"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">Help Center</h6></div></a></div><div class="b-mb-15"></div></div></div><div class=""><a href="/login"><div class="nav-link  "><h6 class="align" style="text-wrap:initial">Sign In</h6></div></a></div><div class="b-pl-10"><a class="button color-button-g3 " data-track="click_submit_a_preprint_button" data-track-context="Submit Preprint main button click" href="/submit"><i class="button-icon fas fa-plus"></i>Submit a Preprint</a></div></div></div></nav></div><div class="rs-container"><div class="tw-mt-12 "><div class=""><div class="tw-max-w-[1600px] tw-mx-auto"><div class="lg:tw-grid lg:tw-grid-cols-10 lg:tw-grid-flow-col"><div class="tw-min-h-screen tw-col-span-6"><div class="tw-flex tw-justify-center lg:tw-justify-start lg:tw-border-r-2 lg:tw-border-gray-50"><div class="tw-max-w-reading tw-w-full tw-overflow-x-scroll _rs-scrollbar lg:tw-pb-20 lg:tw-px-4 lg:tw-pt-2 xl:tw-px-8"><div class="tw-flex tw-pr-4 lg:tw-pr-0 tw-mt-4 lg:tw-hidden tw-pl-3 tw-justify-end"><div class="tw-pr-3"><div class="tw-relative tw-inline-block tw-text-left" data-headlessui-state=""><div><button class="tw-group tw-inline-flex tw-items-center tw-px-3 tw-py-2 tw-transition-all tw-border-2 tw-rounded-md tw-group tw-bg-white tw-border-gray-100 hover:tw-bg-gray-100 focus:tw-outline-none" id="headlessui-menu-button-:Rk9l6:" type="button" aria-haspopup="menu" aria-expanded="false" data-headlessui-state=""><svg xmlns="http://www.w3.org/2000/svg" class="tw-w-5 tw-h-5 tw-text-gray-600" fill="none" viewBox="0 0 24 24" stroke="currentColor"><path d="M16.6187 6.07577C17.6476 6.07404 18.4714 6.44992 19.09 7.20342C19.6858 7.97982 19.9846 8.89392 19.9864 9.94571C19.9879 10.8146 19.8292 11.6266 19.5103 12.3816C19.1915 13.1367 18.7925 13.8234 18.3134 14.4415C17.8114 15.0597 17.2864 15.5979 16.7385 16.0562C16.1676 16.5373 15.6424 16.9383 15.1628 17.2592C14.6832 17.603 14.2949 17.8552 13.998 18.0158C13.6781 18.1763 13.5296 18.2566 13.5525 18.2566L12.7619 17.1947C12.9675 17.1029 13.2416 16.9195 13.5841 16.6446C13.9266 16.3925 14.2691 16.0832 14.6114 15.7168C14.9309 15.3504 15.2161 14.9498 15.4668 14.5149C15.7177 14.1029 15.8427 13.7026 15.8421 13.3139C15.8417 13.0852 15.7041 12.8568 15.4294 12.6286C15.1546 12.4233 14.857 12.1723 14.5363 11.8756C14.2158 11.6017 13.9179 11.2593 13.6429 10.8482C13.3678 10.4599 13.2298 9.97999 13.2289 9.40837C13.228 8.90534 13.3301 8.44786 13.5352 8.03595C13.7175 7.62407 13.9684 7.26924 14.288 6.97145C14.5848 6.69657 14.9388 6.47875 15.3501 6.318C15.7614 6.15725 16.1843 6.07651 16.6187 6.07577ZM7.29256 6.02144C7.81845 6.02055 8.29881 6.13406 8.73363 6.36198C9.16845 6.58989 9.54624 6.89793 9.86701 7.28609C10.1878 7.67426 10.44 8.1197 10.6238 8.62242C10.7848 9.14805 10.8657 9.7081 10.8667 10.3026C10.8687 11.4916 10.6191 12.5895 10.1178 13.5964C9.5936 14.6262 9.02346 15.5075 8.40734 16.2402C7.67713 17.1103 6.84389 17.9006 5.90763 18.611L4.91144 17.6866C5.11699 17.5491 5.36814 17.3314 5.66488 17.0337C5.93876 16.736 6.20111 16.3811 6.45192 15.9691C6.67992 15.5801 6.88501 15.1681 7.06719 14.7334C7.22651 14.2987 7.30583 13.8756 7.30513 13.464C7.30467 13.1896 7.13279 12.9612 6.78951 12.7789C6.44623 12.5966 6.06857 12.3686 5.65653 12.0949C5.2445 11.8212 4.86663 11.4674 4.52292 11.0336C4.17925 10.6226 4.00678 10.0398 4.00551 9.28526C4.00473 8.82796 4.09548 8.4048 4.27774 8.01579C4.46 7.62677 4.71094 7.28337 5.03055 6.98559C5.32729 6.68784 5.68129 6.44716 6.09255 6.26355C6.48099 6.10283 6.88099 6.02213 7.29256 6.02144Z" stroke="currentColor" fill="currentColor"></path></svg><p class="tw-antialiased tw-hidden tw-ml-2 tw-text-sm tw-font-bold tw-text-gray-700 group-hover:tw-underline md:tw-block lg:tw-hidden xl:tw-block">Cite</p></button></div></div></div><div class="last:tw-pr-0"><div class="tw-relative tw-inline-block tw-text-left" data-headlessui-state=""><div><button class="tw-group tw-inline-flex tw-items-center tw-px-3 tw-py-2 tw-transition-all tw-border-2 tw-rounded-md tw-group tw-bg-white tw-border-gray-100 hover:tw-bg-gray-100 focus:tw-outline-none" id="headlessui-menu-button-:Rm9l6:" type="button" aria-haspopup="menu" aria-expanded="false" data-headlessui-state=""><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" aria-hidden="true" class="tw-w-5 tw-h-5 tw-text-gray-600"><path stroke-linecap="round" stroke-linejoin="round" d="M8.684 13.342C8.886 12.938 9 12.482 9 12c0-.482-.114-.938-.316-1.342m0 2.684a3 3 0 110-2.684m0 2.684l6.632 3.316m-6.632-6l6.632-3.316m0 0a3 3 0 105.367-2.684 3 3 0 00-5.367 2.684zm0 9.316a3 3 0 105.368 2.684 3 3 0 00-5.368-2.684z"></path></svg><p class="tw-antialiased tw-hidden tw-ml-2 tw-text-sm tw-font-bold tw-text-gray-700 group-hover:tw-underline md:tw-block lg:tw-hidden xl:tw-block">Share</p></button></div></div></div><a href="https://www.researchsquare.com/article/rs-7472898/v1.pdf?c=1756738163000" target="_blank" rel="noopener noreferrer" class="tw-text-blue-600 hover:tw-text-blue-800 hover:tw-underline tw-inline-flex tw-items-center tw-px-3.5 tw-py-1.5 tw-transition-all tw-border-2 tw-rounded-md tw-group tw-border-blue-50 tw-bg-blue-50 hover:tw-bg-blue-100 hover:tw-border-blue-100 focus:tw-outline-none tw-text-blue-600 hover:tw-text-blue-800 hover:tw-underline tw-ml-3" data-track="content_download" data-track-context="article pdf" data-track-category="Posted" data-track-content-type="Systematic Review" data-track-label="rs-7472898"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" aria-hidden="true" class="tw-w-5 tw-h-5"><path stroke-linecap="round" stroke-linejoin="round" d="M12 10v6m0 0l-3-3m3 3l3-3m2 8H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"></path></svg><span class="tw-antialiased tw-ml-2 tw-text-sm tw-font-bold"><span class="tw-hidden xl:tw-contents">Download</span> PDF</span></a></div><div class="tw-py-4 tw-border-b-2 tw-border-gray-100"><div class="tw-px-4"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black tw-pb-2">Systematic Review</p><h1 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-2xl sm:tw-text-3xl"><p>Neuroimaging of affective symptoms in Lewy body dementia: A systematic review</p></h1></div></div><div class="tw-px-4"><div class="tw-flex tw-items-start tw-justify-between"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-3 tw-w-full"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black">Naomi Mullis, Laura M Wright</p></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div></div><div class="tw-py-3 md:tw-px-1.5 tw-border-gray-100 tw-bg-gray-50 lg:tw-bg-white lg:tw-border-0 lg:tw-px-0 lg:tw-py-0"><div class="tw-mx-2.5 lg:tw-mx-0 tw-border-2 tw-border-gray-100 tw-bg-white tw-rounded-lg lg:tw-mb-1 tw-max-w-xl lg:tw-max-w-none"><div class="tw-px-4"><button type="button" class="tw-min-w-full focus:tw-outline-none tw-group"><div class="tw-flex tw-items-center tw-justify-between"><div class="tw-w-full tw-py-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-red-800 tw-font-bold">This is a preprint; it has not been peer reviewed by a journal.</p></div><div class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700 tw-my-2 tw-flex tw-items-center tw-duration-300 tw-transform tw-bg-gray-100 group-hover:tw-bg-gray-200"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black tw-text-gray-800 group-hover:tw-text-gray-900 tw-flex"></p><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-text-gray-800 group-hover:tw-text-gray-900 tw-h-6 tw-w-6 tw-flex-shrink-0 tw-rounded-full tw-transform tw-duration-300"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-px-4"><div class="tw-border-t-2 tw-border-gray-100 tw-py-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black">https://doi.org/<!-- -->10.21203/rs.3.rs-7472898/v1</p><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black">This work is licensed under a <!-- -->CC BY 4.0<!-- --> License</p></div></div></div><div class="tw-mx-2.5 lg:tw-mx-0 tw-border-2 tw-border-gray-100 tw-bg-white tw-rounded-lg lg:tw-hidden tw-max-w-xl lg:tw-max-w-none tw-mt-3 tw-mb-0"><div class="tw-px-4"><button type="button" class="tw-min-w-full focus:tw-outline-none tw-group"><div class="tw-flex tw-items-center tw-justify-between"><div class="tw-w-full tw-py-2"><div class="tw-flex tw-items-center"><h3 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-base">Status:</h3><div class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700 tw-ml-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-color-gray-800">Posted</p></div></div></div><div class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700 tw-my-2 tw-flex tw-items-center tw-duration-300 tw-transform tw-bg-gray-100 group-hover:tw-bg-gray-200"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black tw-text-gray-800 group-hover:tw-text-gray-900 tw-flex"></p><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-text-gray-800 group-hover:tw-text-gray-900 tw-h-6 tw-w-6 tw-flex-shrink-0 tw-rounded-full tw-transform tw-duration-300"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-px-4 tw-border-t-2 tw-border-gray-100"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><div class="tw-py-2"><div class="tw-text-left"><h3 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-base">Version <!-- -->1</h3><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black tw-text-gray-700">posted<!-- --> </p></div></div></div><div class="tw-pt-1"><div class="tw-pb-1"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black"><span class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700 tw-flex tw-justify-center tw-w-full tw-mb-2">You are reading this <!-- -->latest<!-- --> <!-- -->preprint<!-- --> version</span></p></div></div></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Abstract</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><div class="tw-text-base tw-antialiased tw-leading-relaxed tw-text-left tw-text-black md:tw-leading-loose _fulltext-content"><span style="display:block"><div><h2>Background</h2><p>Affective symptoms, such as depression, anxiety and apathy, are highly prevalent in Lewy body diseases (LBDs), including both Parkinson’s disease and dementia with Lewy bodies. Despite their association with cognitive decline, their underlying neuropathological mechanisms, in the context of cognitive impairment, remain poorly understood. This systematic review examines the neural correlates of affective symptoms in cognitively impaired LBD based on anatomical, functional, metabolic and neurotransmitter imaging studies.</p><h2>Methods</h2><p>Literature searches conducted using PubMed, PsychINFO and Web of Science, identified eighteen eligible studies, including 785 participants, that included assessments of depression, anxiety or apathy; an acceptable method of neuroimaging; and participants with a diagnosis of LBD and evidence of cognitive impairment. A narrative synthesis of their findings is provided.</p><h2>Results</h2><p>Significant heterogeneity in imaging techniques, study protocols and cohort characteristics were identified. Half of the studies did not report significant findings, and only dopaminergic imaging was used by more than one study within the same clinical subgroup. Some evidence highlights involvement of intrinsic brain networks, such as the default mode and salience networks, in affective symptom manifestation. Additionally, two studies found associations between affective symptoms and cholinergic denervation, providing a potential neuropathological connection between neuropsychiatric and cognitive decline in LBD.</p><h2>Conclusions</h2><p>The paucity of studies, and heterogeneity within them, significantly hinder the development of robust hypotheses regarding the neuropathology of affective symptoms in LBD cognitive impairment. This review therefore emphasises the need for more targeted research to understand these underlying mechanisms to inform future therapeutic strategies.</p></div></span></div><div class="tw-flex tw-flex-wrap tw-pb-3"><div class="tw-my-2 tw-mr-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black"><a href="/browse?subjectArea=Neurology" class="tw-text-blue-600 hover:tw-text-blue-800 hover:tw-underline"><span class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-blue-50 hover:tw-bg-blue-100 tw-transition">Neurology</span></a></p></div><div class="tw-my-2 tw-mr-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black"><a href="/browse?subjectArea=Psychiatry" class="tw-text-blue-600 hover:tw-text-blue-800 hover:tw-underline"><span class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-blue-50 hover:tw-bg-blue-100 tw-transition">Psychiatry</span></a></p></div><div class="tw-my-2 tw-mr-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black"><span class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700">Lewy body dementia</span></p></div><div class="tw-my-2 tw-mr-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black"><span class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700">affective symptoms</span></p></div><div class="tw-my-2 tw-mr-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black"><span class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700">neuroimaging</span></p></div><div class="tw-my-2 tw-mr-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black"><span class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700">apathy</span></p></div><div class="tw-my-2 tw-mr-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black"><span class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700">depression</span></p></div><div class="tw-my-2 tw-mr-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black"><span class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700">anxiety</span></p></div></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Figures</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><div class="tw-flex tw-flex-wrap tw-items-end tw-pt-2"><button class="tw-mb-4 tw-mr-4 focus:tw-outline-none tw-group" type="button" tabindex="0"><img alt="Figure 1" loading="lazy" width="100" height="100" decoding="async" data-nimg="1" class="tw-mb-2 tw-border-2 tw-border-gray-100 tw-rounded-lg group-hover:tw-border-gray-200" style="color:transparent" srcSet="/_next/image?url=https%3A%2F%2Fassets-eu.researchsquare.com%2Ffiles%2Frs-7472898%2Fv1%2F59c905d2c2bb7fc66b5bfd2e.png%3FmaxDims%3D150x150&amp;w=128&amp;q=75 1x, /_next/image?url=https%3A%2F%2Fassets-eu.researchsquare.com%2Ffiles%2Frs-7472898%2Fv1%2F59c905d2c2bb7fc66b5bfd2e.png%3FmaxDims%3D150x150&amp;w=256&amp;q=75 2x" src="/_next/image?url=https%3A%2F%2Fassets-eu.researchsquare.com%2Ffiles%2Frs-7472898%2Fv1%2F59c905d2c2bb7fc66b5bfd2e.png%3FmaxDims%3D150x150&amp;w=256&amp;q=75"/><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black group-hover:tw-underline">Figure 1</p></button></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Introduction</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><div class="tw-text-base tw-antialiased tw-leading-relaxed tw-text-left tw-text-black md:tw-leading-loose _fulltext-content"><span style="display:block"><div><p>Lewy body diseases (LBDs), including Parkinson’s disease (PD), PD dementia (PDD) and dementia with Lewy bodies (DLB), are the second leading cause of neurodegenerative dementia after Alzheimer’s Disease (AD) [<span citationid="CR1" class="CitationRef">1</span>]. Clinical features of LBDs can include parkinsonian motor symptoms, cognitive decline and neuropsychiatric symptoms such as visual hallucinations, and sleep disorders [<span citationid="CR2" class="CitationRef">2</span>, <span citationid="CR3" class="CitationRef">3</span>]. Alongside core features, LBDs are typically accompanied by a high volume of supportive symptoms that add to clinical complexity. Affective symptoms, namely anxiety, apathy and depression, are common and debilitating supportive features of LBDs [<span citationid="CR4" class="CitationRef">4</span>]. Such symptoms are highly prevalent in neurodegenerative conditions [<span citationid="CR5" class="CitationRef">5</span>] and particularly common in PDD and DLB when compared with other dementia subtypes [<span additionalcitationids="CR7" citationid="CR6" class="CitationRef">6</span>–<span citationid="CR8" class="CitationRef">8</span>]. Furthermore, anxiety, apathy and depression in LBD have been identified as some of the primary symptoms associated with reductions in quality of life [<span additionalcitationids="CR10 CR11 CR12" citationid="CR9" class="CitationRef">9</span>–<span citationid="CR13" class="CitationRef">13</span>] and increases in cognitive decline [<span additionalcitationids="CR15 CR16 CR17 CR18" citationid="CR14" class="CitationRef">14</span>–<span citationid="CR19" class="CitationRef">19</span>], motor symptom severity [<span citationid="CR9" class="CitationRef">9</span>, <span citationid="CR20" class="CitationRef">20</span>, <span citationid="CR21" class="CitationRef">21</span>], and caregiver burden [<span citationid="CR22" class="CitationRef">22</span>, <span citationid="CR23" class="CitationRef">23</span>].</p><p>Despite their prevalence, the underlying mechanisms of affective symptoms in LBD remain poorly understood. Moreover, most research examining the neural correlates of neuropsychiatric symptoms in LBD has been conducted primarily in cognitively healthy PD, excluding the cognitively impaired LBD groups that these symptoms most frequently affect [<span citationid="CR24" class="CitationRef">24</span>, <span citationid="CR25" class="CitationRef">25</span>]. This exemption of cognitively impaired cohorts from the literature is of particular significance given the established pathophysiological differences between cognitively healthy PD, at one end of the LBD spectrum, and the dementia syndromes of PDD and DLB at the other, which may include a greater burden of AD co-pathology and a more severe cholinergic degeneration [<span additionalcitationids="CR27" citationid="CR26" class="CitationRef">26</span>–<span citationid="CR28" class="CitationRef">28</span>]. Given the well-established association between affective symptoms and cognitive decline [<span additionalcitationids="CR15 CR16" citationid="CR14" class="CitationRef">14</span>–<span citationid="CR17" class="CitationRef">17</span>, <span citationid="CR19" class="CitationRef">19</span>], the relative paucity of research in Lewy body dementias (PDD and DLB) represents a distinct gap in the literature.</p><p>Previous reviews of neuroimaging studies conducted in cognitively healthy PD have revealed multiple structural and functional brain changes associated with apathy, depression and anxiety [<span citationid="CR24" class="CitationRef">24</span>, <span citationid="CR25" class="CitationRef">25</span>, <span citationid="CR29" class="CitationRef">29</span>] and despite a paucity of neuroimaging studies in DLB, neurochemical and neuropathological research has revealed similar associations between affective symptoms and neurotransmission pathways in both PD and DLB [<span additionalcitationids="CR31 CR32 CR33 CR34 CR35" citationid="CR30" class="CitationRef">30</span>–<span citationid="CR36" class="CitationRef">36</span>]. In the wider psychiatric literature, affective states related to psychiatric disorders have been postulated to result from specific changes in functional connectivity both within and between intrinsic resting-state networks relating to impairments in neurotransmission, such as those characteristic of LBDs [<span citationid="CR37" class="CitationRef">37</span>]. Moreover, converging evidence suggesting that certain brain regions, such as the subgenual anterior cingulate cortex, play a significant role in mood disorders [<span citationid="CR38" class="CitationRef">38</span>], has similarly been reflected in neuroimaging studies of such symptoms in cognitively healthy PD and neuropathological studies of DLB [<span additionalcitationids="CR40" citationid="CR39" class="CitationRef">39</span>–<span citationid="CR41" class="CitationRef">41</span>]. Neural correlates of anxiety and apathy have shown similar convergence across psychiatric and PD literature, suggesting that LBDs may exacerbate mechanisms underlying affective symptoms, resulting in an increased prevalence among these patient groups [<span citationid="CR29" class="CitationRef">29</span>, <span citationid="CR42" class="CitationRef">42</span>]. What remains unclear however, are the specific neuropathological changes contributing to the increased severity and prevalence of affective symptoms in the context of cognitive decline.</p><p>Although DLB and PDD are may be considered two clinically distinct entities, the historical debate regarding their nosological distinction is ongoing [<span citationid="CR43" class="CitationRef">43</span>, <span citationid="CR44" class="CitationRef">44</span>]. Both DLB and PDD are underpinned by similar pathophysiological processes [<span citationid="CR45" class="CitationRef">45</span>, <span citationid="CR46" class="CitationRef">46</span>] and clinical profiles [<span citationid="CR3" class="CitationRef">3</span>, <span citationid="CR47" class="CitationRef">47</span>] to the extent that both may be preceded by a prodromal period of mild cognitive impairment (MCI) [<span citationid="CR48" class="CitationRef">48</span>, <span citationid="CR49" class="CitationRef">49</span>]. In clinical practice, a rather arbitrary ‘one year rule’ defines PDD based on the initial appearance of motor symptoms at least one year prior to cognitive decline, although no symptoms definitively distinguish PDD from DLB at the dementia stages [<span citationid="CR50" class="CitationRef">50</span>]. The present review therefore examines the PDD and DLB literature in aggregate, including studies of prodromal MCI groups, to synthesise current evidence regarding neural correlates of affective symptoms across the spectrum of Lewy body dementias.</p><p>The aim of this review is to identify brain regions involved in affective symptoms in Lewy body dementias based on anatomical, functional, metabolic and neurotransmitter imaging studies. Moreover, we aim to provide information on how these neural correlates may differ across symptom type, disease stage and disease subtype. Finally, we aim to inform the methods of prospective neuroimaging studies seeking to investigate the neural basis of affective symptoms in these disease groups.</p></div></span></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Methods</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><div class="tw-text-base tw-antialiased tw-leading-relaxed tw-text-left tw-text-black md:tw-leading-loose _fulltext-content"><span style="display:block"><div><p>The review protocol for the current systematic review was registered in PROSPERO following PRISMA guidelines (PROSPERO ID CRD42024539741) [<span citationid="CR51" class="CitationRef">51</span>]. The review protocol can be accessed here: <span class="ExternalRef"><span class="RefSource">https://www.crd.york.ac.uk/PROSPERO/view/CRD42024539741</span><span address="https://www.crd.york.ac.uk/PROSPERO/view/CRD42024539741" targettype="URL" class="RefTarget"></span></span>. Literature searches were conducted in PubMed, PsychINFO and Web of Science Core Collection. The search terms used included terms related to Parkinson’s OR Lewy bodies OR synucleinopathies AND cognitive impairment OR cognitive decline OR cognitive complaint OR dementia AND imaging (magnetic resonance imaging, positron emission tomography, single photon emission computed tomography, diffusion tensor imaging etc.) AND apathy OR anxiety OR depression OR affective disorder OR mood disorder. A detailed list of search terms is available in <b>Table S1</b>. The search was not limited by date so all studies available until the date of the search (15th July 2025) were included. These searches resulted in the identification of 1841 articles.</p><p>Following the removal of duplicates, 1315 articles were included in title and abstract screening. Inclusion criteria required that studies must include the following: participants with a diagnosis of LBD (either PD or DLB) with evidence of cognitive impairment; an assessment of anxiety, apathy or depression; any method of neuroimaging with outcomes including grey matter volume, cortical thickness, white matter microstructural integrity, blood-oxygen-level-dependent signal (or network connectivity strength), glucose metabolism or binding-ratio values; a categorical comparison between patients with and without anxiety, apathy or depression on imaging parameters or a correlation of imaging parameters with the severity of the neuropsychiatric symptom as a continuous variable. Exclusion criteria included: foreign language articles for which an English translation was unavailable; review articles reporting no original data; studies focused on diseases other than PD or DLB (including other synucleinopathies); studies that did not include a cognitively impaired participant group or that pooled cognitively unimpaired and impaired groups for imaging analysis; studies that did not utilise standard diagnostic criteria for cognitive impairment or LBD; studies without any assessments of anxiety, apathy or depression; studies without neuroimaging; studies that did not analyse anxiety, apathy or depression in relation to neuroimaging outcomes and studies in which the neuroimaging outcomes were not regionally quantified (e.g., amyloid-positive PET vs amyloid-negative).</p><p>Eligibility was determined independently by two researchers (L.W. and N.M.). Any discrepancies were discussed until a consensus could be reached. Following title and abstract screening, 142 articles were sourced for full text screening. Full details of the article screening process can be found in <b>Fig. 1</b>.</p><p>Data extraction and quality assessment were carried out by two researchers (L.W. and N.M.). A data extraction sheet included manuscript details (authors, title, year of publication and journal), demographic data (sample size, age, gender, disease duration, education, medication, global cognitive function), neuropsychiatric scales and scores and details of neuroimaging (methods, outcome measures and findings). Peak coordinates and effect size measures for regions found to have a significant relationship with affective symptom severity were also collected where possible. Demographic data were recorded in two separate tables for PDD and DLB groups. Similarly, imaging data and results were recorded in two separate tables for PDD and DLB groups.</p></div></span></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Results</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><div class="tw-text-base tw-antialiased tw-leading-relaxed tw-text-left tw-text-black md:tw-leading-loose _fulltext-content"><span style="display:block"><div><p>Eighteen imaging studies met the inclusion criteria and were included for systematic review. Figure 1 outlines the study selection procedure. Of the studies included, six utilized neurotransmitter/transporter imaging methods [<span citationid="CR36" class="CitationRef">36</span>, <span additionalcitationids="CR53 CR54 CR55" citationid="CR52" class="CitationRef">52</span>–<span citationid="CR56" class="CitationRef">56</span>], four were anatomical MRI studies [<span additionalcitationids="CR58 CR59" citationid="CR57" class="CitationRef">57</span>–<span citationid="CR60" class="CitationRef">60</span>], four utilized resting-state functional MRI (fMRI) [<span additionalcitationids="CR62 CR63" citationid="CR61" class="CitationRef">61</span>–<span citationid="CR64" class="CitationRef">64</span>], one was a metabolic imaging study [<span citationid="CR65" class="CitationRef">65</span>], one measured regional cerebral blood flow [<span citationid="CR66" class="CitationRef">66</span>], one examined amyloid (Aβ) PET [<span citationid="CR67" class="CitationRef">67</span>] and one utilized diffusion tensor imaging [<span citationid="CR68" class="CitationRef">68</span>]. Of the studies, seventeen included a measure of depression, eight included a measure of anxiety and seven included a measure of apathy. Combined, the included studies involved 785 participants with Lewy body related cognitive impairment including: DLB or MCI with Lewy bodies (MCI-LB) (n = 492) and PDD or PD related MCI (PD-MCI) (n = 293). <b>Tables 1</b> and <b>2</b> outline the demographic data of PDD or PD-MCI and DLB or MCI-LB groups, respectively. According to the quality assessment, nine studies received a score of “good,” and nine received a score of “moderate.” Further information about this quality assessment can be found in the Supplementary Material. Given the limited number of studies and the heterogeneity between them, meta-analysis was not possible and therefore only a narrative synthesis of the results is provided.</p><p><b>-Please insert Tables 1 and 2 about here-</b></p><p><em>Anatomical MRI Studies</em></p><p>Together, the four anatomical MRI studies comprised 28 participants diagnosed with PD with normal cognition (PD-NC), 77 with PD-MCI, 20 with PDD, 117 with DLB, 119 with AD and 53 healthy controls (HC). Two of the studies, by Chang et al. ([<span citationid="CR58" class="CitationRef">58</span>] and Querry et al. [<span citationid="CR60" class="CitationRef">60</span>], were based on 3-T MRI T1-weighted scans. The remaining two, by Jaramillo-Jimenez et al.[<span citationid="CR59" class="CitationRef">59</span>] and Almeida et al.[<span citationid="CR57" class="CitationRef">57</span>], were based on 1.5-T MRI T1-weighted scans. Two studies analysed grey matter volume using a region of interest approach [<span citationid="CR57" class="CitationRef">57</span>, <span citationid="CR59" class="CitationRef">59</span>] and two used voxel-based morphometry [<span citationid="CR58" class="CitationRef">58</span>, <span citationid="CR60" class="CitationRef">60</span>]. Chang et al. [<span citationid="CR58" class="CitationRef">58</span>] additionally implemented a structural covariance analysis to analyse structural connectivity. Three of the four studies assessed depression; two in PDD or PD-MCI groups using the Geriatric Depression Scale (GDS) [<span citationid="CR57" class="CitationRef">57</span>, <span citationid="CR58" class="CitationRef">58</span>] and one in DLB and AD participants using the Mini International Neuropsychiatric Interview (MINI) [<span citationid="CR60" class="CitationRef">60</span>]. The study by Jaramillo-Jimenez et al. [<span citationid="CR59" class="CitationRef">59</span>] assessed a range of neuropsychiatric symptoms in participants with AD and DLB, using the 12 items of the Neuropsychiatric Inventory (NPI) [<span citationid="CR69" class="CitationRef">69</span>].</p><p>The study by Almeida et al. (2003) found no association between caudate volume and depression in their PDD group. In their whole-brain voxel-based morphometry analysis, Chang et al., (2017) found PD-MCI patients with depression to have greater grey matter volume in the right fusiform gyrus, right hippocampus and bilateral superior parietal gyri than those without. In the fronto-insula, however, those with depression had lower grey matter volume. GDS scores were also found to positively correlate with volume in the right fusiform gyrus and the left superior parietal lobe and negatively correlate with volume in the right fronto-insula and the left lingual gyrus. Finally, eight clusters including the left anterior cingulate, left calcarine, left caudate, right hippocampus, right inferior frontal gyrus, left lingual gyrus, left rolandic operculum, and right superior frontal lobe demonstrated stronger structural covariance with the right fronto-insula cortex in the non-depressed than in the depressed PD-MCI group. Results from all studies involving PDD or PD-MCI groups can be found in <b>Table 3</b>.</p><p>Of the two studies that included DLB groups, the study by Querry et al., (2024) found that DLB patients classified as depressed had lower grey matter volume in right middle frontal and posterior cingulate regions than those without depression [<span citationid="CR60" class="CitationRef">60</span>]. Whereas, the study by Jaramillo-Jimenez et al. (2021) found no association between amygdala volume and longitudinal development of affective symptoms in DLB. Results for DLB studies are presented in <b>Table 4</b>.</p><p><b>-Please insert Tables 3 and 4 about here-</b></p><p><em>Functional MRI Studies</em></p><p>Four out of the 18 studies examined neuropsychiatric symptoms in LBD using fMRI [<span additionalcitationids="CR62 CR63" citationid="CR61" class="CitationRef">61</span>–<span citationid="CR64" class="CitationRef">64</span>].  Three studies included participants with PD-MCI and two included participants with MCI-LB or DLB amounting to a total of 83 PD-MCI, 61 PD-NC, 28 MCI-LB, 66 DLB and 54 HC across studies. All studies utilized a 3T MRI scanner. Wright et al. [<span citationid="CR64" class="CitationRef">64</span>] utilized the NPI to evaluate apathy and depression (as a composite affective disorder factor) and anxiety. The studies by Xing et al. [<span citationid="CR61" class="CitationRef">61</span>] and Zhang et al. [<span citationid="CR62" class="CitationRef">62</span>] used the Hamilton Depression Rating Scale (HAMD) and the Hamilton Anxiety Rating Scale (HAMA) to evaluate depression and anxiety symptoms. The study by Querry et al. [<span citationid="CR63" class="CitationRef">63</span>] used the MINI to evaluate depression.</p><p>Each study used slightly different outcome measures. The study by Xing et al. [<span citationid="CR61" class="CitationRef">61</span>] assessed regional brain activity using regional homogeneity whereas the remaining studies all focused on seed-based functional connectivity indices. Zhang et al. [<span citationid="CR62" class="CitationRef">62</span>] assessed seed-based connectivity of cholinergic basal forebrain nuclei whereas Querry et al. [<span citationid="CR63" class="CitationRef">63</span>] and Wright et al. [<span citationid="CR64" class="CitationRef">64</span>] assessed seed-based connectivity of multiple resting-state networks. While Xing et al.[<span citationid="CR61" class="CitationRef">61</span>] found no significant associations between regional homogeneity values and either of their neuropsychiatric measures, Zhang et al. [<span citationid="CR62" class="CitationRef">62</span>] found a significant positive correlation between HAMD scores and functional connectivity between the right nucleus basalis of Meynert and right middle cingulate and paracingulate gyri in PD-MCI. Wright et al. [<span citationid="CR64" class="CitationRef">64</span>] also found significantly greater connectivity associated with both anxiety and affective disorder (depression and apathy), in PD-MCI, between the precuneus seed of the default mode network (DMN) and the subgenual cingulate, and between the orbitofrontal seed of the limbic network and areas of the DMN including the precuneus and subgenual cingulate. They also found affective disorder and anxiety severity to be associated with weaker connectivity between the limbic orbitofrontal seed and the brainstem and weaker connectivity between the salience network and the subgenual cingulate. No significant correlations were found between symptom severity and functional connectivity in the MCI-LB group, however. In DLB, however, the study by Querry et al. (2025) found significant positive correlations between MINI scores and functional connectivity between both the orbitofrontal cortex and inferior temporal gyrus and areas of the occipital lobe. Conversely, negative correlations were found between the MINI scores and functional connectivity between the inferior frontal cortex and occipital regions. The depressed DLB group were additionally found to have weaker connectivity between the cerebellum and lateral prefrontal cortex and greater connectivity between the lateral parietal cortex and the superior temporal gyrus, although these findings were only demonstrated at an uncorrected threshold.</p><p><em>Neurotransmitter/Neurotransporter Studies</em></p><p>Neurotransmitter imaging studies were the most abundant studies included for review. None of the neurotransmitter studies included a cognitively impaired PD group. Three studies involving a total of 71 participants with DLB, 20 with prodromal DLB (MCI-LB) and 10 with AD, investigated dopamine transporter (DAT) striatal binding ratios using <sup>123</sup>I-FP-CIT single-photon emission computed tomography (SPECT) [<span citationid="CR36" class="CitationRef">36</span>, <span citationid="CR52" class="CitationRef">52</span>, <span citationid="CR54" class="CitationRef">54</span>, <span citationid="CR55" class="CitationRef">55</span>] and a further two studies involving a total of 65 DLB patients investigated DAT binding ratios using either <sup>18</sup>F-FE-PE2I PET [<span citationid="CR56" class="CitationRef">56</span>] or <sup>18</sup>F-FP-CIT PET [<span citationid="CR55" class="CitationRef">55</span>]. An additional single study of 11 participants with DLB and 12 HC investigated the density of vesicular acetylcholine transporter (VAchT) binding sites in several regions of interest within cholinergic pathways using <sup>123</sup>I-iodobenzovesamicol SPECT [<span citationid="CR53" class="CitationRef">53</span>]. In five of the six studies, neuropsychiatric symptoms were correlated with DAT binding ratios. In one study, VAchT binding potentials were compared between apathetic and non-apathetic DLB patients. Four studies used the NPI to assess neuropsychiatric symptoms [<span citationid="CR36" class="CitationRef">36</span>, <span additionalcitationids="CR54" citationid="CR53" class="CitationRef">53</span>–<span citationid="CR55" class="CitationRef">55</span>], one used the GDS to measure depression [<span citationid="CR56" class="CitationRef">56</span>], and one used a questionnaire with 12 specific questions corresponding to the non-motor symptoms associated with LBD [<span citationid="CR52" class="CitationRef">52</span>].</p><p>In three of the six studies, no associations were found between DAT binding and any neuropsychiatric symptoms [<span citationid="CR52" class="CitationRef">52</span>, <span citationid="CR54" class="CitationRef">54</span>]. In the remaining studies, depression and apathy, as measured by the NPI, were found to be negatively correlated with DAT binding in the caudate [<span citationid="CR36" class="CitationRef">36</span>] anxiety was found to negatively correlate with DAT binding in the ventral striatum [<span citationid="CR55" class="CitationRef">55</span>], and VAchT binding potential values in the anterior cingulate were found to be significantly lower in DLB patients with apathy than without [<span citationid="CR53" class="CitationRef">53</span>].</p><p><em>Other Imaging Techniques</em></p><p>The remaining studies utilized a range of different techniques to examine neuropsychiatric neural correlates in DLB and PD. A perfusion SPECT study examined regional cerebral blood flow in 95 DLB patients [<span citationid="CR66" class="CitationRef">66</span>]. An <sup>18</sup>FDG-PET study examined glucose metabolism in patients with DLB (n = 28), AD (n = 741) and frontotemporal lobar degeneration (n = 137) [<span citationid="CR65" class="CitationRef">65</span>]. An <sup>18</sup>F-florbetapir PET study examined regional Aβ deposition in 21 patients with PDD, 20 with AD and 9 HC [<span citationid="CR67" class="CitationRef">67</span>] and a diffusion tensor imaging study examined free water values in the nucleus basalis of Meynert in 59 HC, 57 patients with idiopathic REM sleep behavior disorder, 57 patients with PD-NC, and 64 patients with PD-MCI using a 3T MRI scanner [<span citationid="CR68" class="CitationRef">68</span>].</p><p>Three of the four studies used correlational methods to determine the relationship between outcome measures and neuropsychiatric symptoms. The study by Murayama et al., [<span citationid="CR66" class="CitationRef">66</span>] however, compared regional cerebral blood flow between DLB participants with and without depression. The studies used various methods to measure affective symptoms including the NPI, GDS and the State Trait Anxiety Inventory. Murayama et al.[<span citationid="CR66" class="CitationRef">66</span>] did not explicitly state the specific neuropsychiatric measure used but implied that the presence of depression was determined as part of the clinical diagnostic protocol.</p><p>Of all the studies, only the study by Murayama et al. [<span citationid="CR66" class="CitationRef">66</span>] found findings of significance. Free-water values, regional Aβ deposition and glucose metabolism were all found not to be associated with affective symptoms in either DLB, PDD or PD-MCI groups. Regional cerebral blood flow however was found to be greater in the angular gyrus and upper precuneus of DLB patients with depression than in those without.</p></div></span></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Discussion</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><div class="tw-text-base tw-antialiased tw-leading-relaxed tw-text-left tw-text-black md:tw-leading-loose _fulltext-content"><span style="display:block"><div><p>This review aimed to elucidate the structural and functional neural correlates of affective symptoms in Lewy body dementias based on anatomical, functional, metabolic and neurotransmitter neuroimaging studies. The overwhelming take-away was the sheer paucity of research in this area. Given the limited data and few studies analyzing the relationship between affective symptoms and imaging metrics as a primary aim, imaging-based signatures of such symptoms in cognitively impaired LBD groups remain elusive and as such our aim to provide details regarding potential differences between disease stages and disease subtypes could only be partially met. Although a handful of studies reported some significant findings, there is little consensus within the currently available literature, highlighting a persisting need for further hypothesis driven research in larger, more diverse cohorts.</p><p>Of the eighteen studies included in the present review, only nine demonstrated a significant association between a given measure of anxiety, apathy or depression and brain structure or function. Most studies (17/18) included a measure of depression with far fewer investigating anxiety or apathy. As such, significant findings were predominantly limited to this symptom, with only two studies highlighting significant findings related to anxiety in cognitively impaired PD or DLB and only two highlighting a significant finding related to apathy in DLB.</p><p>In cognitively impaired PD groups, only three studies identified significant neural correlates of affective symptom severity, two assessing functional connectivity and one assessing grey matter volume, all of which focused on PD-MCI. The study by Chang et al. [<span citationid="CR58" class="CitationRef">58</span>] identified multiple regions of both higher and lower grey matter volume in several disparate brain regions among PD-MCI with depression when compared to those without. Although some previous studies have identified positive correlations between depression and volumetric or cortical thickness measures in PD [<span citationid="CR70" class="CitationRef">70</span>, <span citationid="CR71" class="CitationRef">71</span>], such positive associations are at odds with a range of imaging research that has typically highlighted lower grey matter volume within limbic, prefrontal and insular regions, in depressed PD groups [<span citationid="CR25" class="CitationRef">25</span>, <span citationid="CR72" class="CitationRef">72</span>]. Chang et al.’s study further highlighted a possible breakdown in structural covariance within the salience network in the depressed PD-MCI group compared with the non-depressed group. Such findings may align with functional connectivity analyses of major depressive disorder [<span citationid="CR73" class="CitationRef">73</span>], and even PD-MCI [<span citationid="CR64" class="CitationRef">64</span>], in which hypoconnectivity of the salience network has been found to relate to depression. However, the reliability of structural covariance metrics remains somewhat contentious [<span citationid="CR74" class="CitationRef">74</span>] and as such, further research is needed to validate these findings.</p><p>Functional imaging studies in cognitively impaired PD groups, however, appear to align more clearly with what has previously been established in cognitively healthy PD and broader models of psychopathology. In Wright et al.’s (2025) fMRI study, positive correlations between both ‘affective disorder’ and anxiety severity and functional connectivity were identified particularly between the limbic orbitofrontal cortex, subgenual cingulate, and regions of the DMN. Conversely, negative correlations were found between affective symptom severity and connectivity between the orbitofrontal cortex and the brainstem and between the subgenual cingulate and the salience network. In Zhang et al.’s [<span citationid="CR62" class="CitationRef">62</span>] study, depression severity was additionally found to positively correlate with connectivity of the nucleus basalis of Meynert. Such findings by Wright et al. reflect those of previous research in cognitively healthy PD groups [<span citationid="CR39" class="CitationRef">39</span>, <span citationid="CR40" class="CitationRef">40</span>], and literature from the broader psychiatric field, highlighting the significant involvement of the subgenual cingulate, limbic regions and imbalanced activity across the DMN and salience network in depression and anxiety disorders [<span citationid="CR37" class="CitationRef">37</span>, <span citationid="CR38" class="CitationRef">38</span>]. This contributes towards a hypothesis that aberrant functional network connectivity may be a core underlying mechanism of neuropsychiatric symptoms in PD that is likely heavily influenced by LBD related changes in multiple neurotransmission pathways such as the serotonergic and dopaminergic systems [<span citationid="CR32" class="CitationRef">32</span>, <span citationid="CR34" class="CitationRef">34</span>, <span citationid="CR35" class="CitationRef">35</span>]. The findings by Zhang and colleagues further highlight a significant association between depression severity and connectivity between the cholinergic basal forebrain and cingulate cortex, a brain region frequently implicated in PD related affective symptoms [<span citationid="CR40" class="CitationRef">40</span>, <span citationid="CR64" class="CitationRef">64</span>, <span citationid="CR75" class="CitationRef">75</span>, <span citationid="CR76" class="CitationRef">76</span>]. Earlier reviews of cholinergic deficits in PD have highlighted a potential connection between depression as a risk-factor for cognitive decline in PD and cholinergic dysfunction [<span citationid="CR77" class="CitationRef">77</span>]. Given both early and recent discoveries suggesting an important role of the cholinergic system in mood regulation [<span citationid="CR78" class="CitationRef">78</span>], and the increased cholinergic denervation associated with LBD cognitive decline [<span citationid="CR27" class="CitationRef">27</span>], this finding warrants further investigation as a possible mechanism underlying the observable relationship between cognitive decline and increasing affective symptom severity in LBDs [<span additionalcitationids="CR15 CR16 CR17 CR18" citationid="CR14" class="CitationRef">14</span>–<span citationid="CR19" class="CitationRef">19</span>].</p><p>Far more studies, using a broader variety of techniques, examined affective symptoms in DLB. Of the 11 studies that included a DLB or MCI-LB group, six reported significant findings. Studies in DLB primarily utilized SPECT imaging to assess neurotransmission, with five investigating striatal DAT binding and one investigating the density of VAchT binding within cholinergic pathways. Conversely, none of the studies in cognitively impaired PD groups utilized such neurotransmission imaging techniques, possibly due to a wealth of research already providing evidence for a role of dopaminergic, serotonergic and noradrenergic denervation underlying affective symptoms in cognitively healthy PD [<span citationid="CR79" class="CitationRef">79</span>]. In contrast with PD research that has shown significant correlations between anxiety, apathy and depression and DAT binding [<span citationid="CR29" class="CitationRef">29</span>, <span citationid="CR34" class="CitationRef">34</span>, <span citationid="CR80" class="CitationRef">80</span>], evidence from DLB groups is sparse. Although two of the five DAT imaging studies identified some significant negative correlations between DAT binding in the striatum and either depression, apathy or anxiety in DLB ([<span citationid="CR36" class="CitationRef">36</span>, <span citationid="CR55" class="CitationRef">55</span>], others reported a lack of significant association with any affective symptom [<span citationid="CR52" class="CitationRef">52</span>, <span citationid="CR54" class="CitationRef">54</span>, <span citationid="CR56" class="CitationRef">56</span>]. Furthermore, Roselli et al. [<span citationid="CR36" class="CitationRef">36</span>] demonstrated significant associations between depression and apathy and DAT binding within the caudate but found no association with anxiety. Conversely, Yoo et al. [<span citationid="CR55" class="CitationRef">55</span>] found only anxiety significantly correlated with DAT binding in the ventral striatum while apathy and depression were not associated with binding in any striatal region. Explanations for such discrepancies may lie in the substantial differences in study methodology, including imaging tracer and technique, diagnostic protocols, region of interest definition, and covariates in the analysis. Regardless, the directionality of results is consistent across both studies, with dopaminergic activity deficits within the striatum relating to manifestations of affective symptoms in DLB. Such findings are supported by neuropathological studies in DLB which have highlighted degeneration of dopaminergic pathways in depressed patients [<span citationid="CR31" class="CitationRef">31</span>, <span citationid="CR41" class="CitationRef">41</span>], as well as neuroimaging studies in both cognitively healthy PD and other psychiatric and neurocognitive disorders [<span citationid="CR29" class="CitationRef">29</span>, <span additionalcitationids="CR82" citationid="CR81" class="CitationRef">81</span>–<span citationid="CR83" class="CitationRef">83</span>].</p><p>Aside from DAT-SPECT, Mazère et al.’s SPECT study [<span citationid="CR53" class="CitationRef">53</span>], investigating VAchT, identified significantly lower VAchT binding within the anterior cingulate cortex in apathetic DLB patients compared with HC, despite no such difference being identified in non-apathetic DLB. Despite the limited sample size of this study, the results align with Zhang et al.’s findings [<span citationid="CR62" class="CitationRef">62</span>] demonstrating a significant association between depression and functional connectivity deficits between the nucleus basalis of Meynert and cingulate cortex in PD-MCI, further highlighting the cholinergic system as an emerging area of interest regarding the pathophysiology of affective symptoms in cognitively impaired LBD.</p><p>Of the four functional imaging studies in DLB or MCI-LB, three reported significant findings. Interestingly, Murayama et al.’s study [<span citationid="CR66" class="CitationRef">66</span>] identified significantly greater regional cerebral blood flow in areas corresponding to the DMN in depressed DLB participants, aligning with the DMN hyperconnectivity associated with affective disorder scores identified in PD-MCI by Wright et al.[<span citationid="CR64" class="CitationRef">64</span>]. DMN regions were similarly highlighted by Querry et al.’s (2024) structural study in which depression was found to be negatively associated with grey matter volume within the middle frontal gyrus and precuneus. Such associations between depressive symptoms and DMN alterations are well established in the psychiatric literature and in previous studies in cognitively healthy PD [<span additionalcitationids="CR39" citationid="CR38" class="CitationRef">38</span>–<span citationid="CR40" class="CitationRef">40</span>]. Overactivity of the DMN in relation to negative affective states has been hypothesized to result, in part, from dysfunctional dopaminergic circuits [<span citationid="CR37" class="CitationRef">37</span>], aligning with the denervation and pathological burden within dopaminergic pathways associated with depression in DLB [<span citationid="CR31" class="CitationRef">31</span>, <span citationid="CR41" class="CitationRef">41</span>]. However, it must be noted in this case that such findings were not corroborated by Gan et al.’s <sup>18</sup>FDG-PET study [<span citationid="CR65" class="CitationRef">65</span>] or either of the two fMRI studies in investigating DLB or MCI-LB [<span citationid="CR63" class="CitationRef">63</span>, <span citationid="CR64" class="CitationRef">64</span>]. Rather, Querry et al.’s functional study [<span citationid="CR63" class="CitationRef">63</span>] identified a range of both positive and negative associations between functional connectivity and depression in their DLB group that were largely located between the orbitofrontal and inferior temporal cortex and regions of the occipital lobe, with little to no involvement of regions associated with the DMN. Negative correlations were also identified between depression severity and within-network connectivity of the salience network. Although this may align with hypothesized contributions of salience network hypoconnectivity to negative affective states [<span citationid="CR37" class="CitationRef">37</span>], such findings were only identified at an uncorrected threshold and have yet to be replicated. At present, therefore, little corroboration exists within the literature regarding imaging correlates of affective symptoms in DLB.</p><p><em>Strengths and Limitations</em></p><p>The present review adhered to the PRISMA guidelines for systematic reviews, with a particular strength being the breadth of imaging techniques and symptom measures covered which captures the full spectrum of literature addressing the most common forms of affective symptoms in LBDs. A possible limitation, however, was the decision to exclude electrophysiological techniques, such as electroencephalography and magnetoencephalography, from both the search terms and through screening. The decision to exclude these techniques was made to limit the scope of this review to more easily comparable functional and structural outcome measures. However, such studies may prove beneficial in furthering our understanding of the neural mechanisms underlying affective symptoms in LBDs and as such their exclusion may be considered a limitation.</p><p>One of the main limiting factors of the studies reviewed is that, except for DAT imaging, none of the imaging approaches utilized had been repeated within the same clinical subgroup across more than a single study, providing no opportunity to assess the replicability of the findings. Half of the studies did not identify any significant findings at all, resulting in little corroborating evidence across the literature. Furthermore, only half of the studies reviewed investigated the relationship between affective symptoms and neuroimaging metrics as a primary aim, meaning that not only were hypotheses not formulated around this specific research question, but many studies excluded participants based on the presence of clinically relevant psychiatric symptoms. Currently, therefore, it is hard to reconcile the multiple apparent inconsistencies across neuroimaging studies of affective symptoms in cognitively impaired LBD, given that the evidence base remains so limited. Furthermore, variations in imaging modalities, analysis techniques, neuropsychiatric measures and other confounding factors make the parsing out of valid and reliable findings from the idiosyncrasies of individual studies and disease cohorts significantly challenging.</p><p>A further limitation complicating the investigation of affective symptom neural correlates in Lewy body dementia is the known prevalence of mixed etiologies and co-morbid pathologies that may significantly impact clinical presentations [<span additionalcitationids="CR27" citationid="CR26" class="CitationRef">26</span>–<span citationid="CR28" class="CitationRef">28</span>, <span additionalcitationids="CR85" citationid="CR84" class="CitationRef">84</span>–<span citationid="CR86" class="CitationRef">86</span>]. Of the studies included, only four included an Aβ biomarker and the vast majority of participants were diagnosed based solely on clinical criteria, limiting the possibility to determine pathology specific contributions to affective symptoms. In AD, tau and Aβ burden have not only been directly associated with affective symptoms [<span additionalcitationids="CR88" citationid="CR87" class="CitationRef">87</span>–<span citationid="CR89" class="CitationRef">89</span>], but additionally impact specific neurotransmission systems, such as cholinergic pathways, that have an established role in affective symptom manifestation [<span citationid="CR27" class="CitationRef">27</span>, <span citationid="CR78" class="CitationRef">78</span>, <span citationid="CR90" class="CitationRef">90</span>]. The study by Yoo et al.[<span citationid="CR55" class="CitationRef">55</span>] further replicates the association between affective symptoms and AD pathology in DLB, finding that DLB participants with a high Aβ load demonstrated greater levels of anxiety and overall neuropsychiatric burden than Aβ-negative participants. Current imaging studies are therefore significantly limited by the relatively few well-characterized, pathologically confirmed study cohorts available, a limitation which may be significantly contributing towards the apparent lack of correspondence between some imaging studies and histopathological findings, particularly in DLB [<span citationid="CR31" class="CitationRef">31</span>, <span citationid="CR41" class="CitationRef">41</span>].</p><p>Finally, it is well established within the psychiatric literature that symptoms such as depression, apathy and anxiety are not derived from a set of unitary diseases but rather each consist of a broad spectrum of features and characteristics that may be etiologically diverse across individuals [<span additionalcitationids="CR92" citationid="CR91" class="CitationRef">91</span>–<span citationid="CR93" class="CitationRef">93</span>]. It is reasonable to predict, therefore, that the same is likely true of manifestations of affective symptoms in such complex and multifactorial conditions as Lewy body dementia, where a vast range of potential alterations within neurotransmission pathways and brain networks, resultant of either pure or mixed pathologies, may differentially contribute to symptom manifestation in each individual. Such diversity does not only arise from underlying pathology but is further complicated by the significant clinical overlaps not only between affective symptoms themselves but between affective symptoms and other clinical features of LBD such as motor deficits, sleep disturbance and cognitive fluctuations [<span additionalcitationids="CR95" citationid="CR94" class="CitationRef">94</span>–<span citationid="CR96" class="CitationRef">96</span>]. A final substantial limitation of the current literature is therefore the use of a range of heterogeneous affective symptom rating scales, the validity of which have yet to be adequately assessed in the context of Lewy body dementia. The success of future clinical trials will, therefore, largely rely on research that is able to address such complications to establish meaningful neural correlates of symptom manifestations to provide therapeutic targets for symptomatic therapies.</p></div></span></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Conclusion</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><div class="tw-text-base tw-antialiased tw-leading-relaxed tw-text-left tw-text-black md:tw-leading-loose _fulltext-content"><span style="display:block"><div><p>The findings of this review highlight a substantial gap in the literature that currently significantly limits our pathophysiological understanding of the well-established link between cognitive and neuropsychiatric decline in LBD. Such gaps in knowledge are a considerable hindrance to clinical trials seeking to develop effective interventions for these distressing and quality of life limiting symptoms. Future research should therefore focus on testing well-formulated hypotheses to replicate or extend the findings of earlier imaging studies, with the explicit aim of elucidating neural correlates of affective symptoms in cognitively impaired LBD groups. Optimizing symptom measurement and biomarker characterization of study cohorts may significantly improve future study protocols and consistency across the literature, therefore contributing towards a more robust theoretical basis for future therapeutic targets.</p></div></span></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Declarations</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><div class="tw-text-base tw-antialiased tw-leading-relaxed tw-text-left tw-text-black md:tw-leading-loose _fulltext-content"><span style="display:block"><div><p><span lang="EN-GB">Competing Interests</span></p>
<p><span lang="EN-GB">The authors have no competing interests to declare that are relevant to the content of this article.</span></p>
<p><span lang="EN-GB">Funding</span></p>
<p>NM has no financial disclosures. LMW was supported by a bridging grant from ARUK (ARUK-ECRBF2023B-006) as well as being supported by the NIHR Newcastle Biomedical Research Centre. </p>
<p><span lang="EN-GB">Data availability</span></p>
<p>The data presented in this article may be provided by the authors upon reasonable request.</p>
<p><span lang="EN-GB">Authors Contributions</span></p>
<p><span lang="EN-GB">LMW conceptualised the design and protocol of the review and performed the literature search. Both NM and LMW conducted the screening, data extraction and quality assessment of studies. Both NM and LMW contributed to the writing and editing of the final manuscript.</span></p></div></span></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">References</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><div class="tw-text-base tw-antialiased tw-leading-relaxed tw-text-left tw-text-black md:tw-leading-loose _fulltext-content"><span style="display:block"><div><ol><li><span>Aarsland D, Rongve A, Piepenstock Nore S, Skogseth R, Skulstad S, Ehrt U et al (2008) Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord 26(5):445–452. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1159/000165917</span><span address="10.1159/000165917" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson&#x27;s disease. Mov Disord 22(12):1689–1707. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.21507</span><span address="10.1002/mds.21507" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D et al (2017) Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89(1):88–100. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1212/WNL.0000000000004058</span><span address="10.1212/WNL.0000000000004058" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Ballard C, Aarsland D, Francis P, Corbett A (2013) Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. Drugs Aging 30(8):603–611. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1007/s40266-013-0092-x</span><span address="10.1007/s40266-013-0092-x" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288(12):1475–1483. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1001/jama.288.12.1475</span><span address="10.1001/jama.288.12.1475" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Donaghy PC, Taylor JP, O&#x27;Brien JT, Barnett N, Olsen K, Colloby SJ et al (2018) Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies. Psychol Med 48(14):2384–2390. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1017/s0033291717003956</span><span address="10.1017/s0033291717003956" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Bjoerke-Bertheussen J, Ehrt U, Rongve A, Ballard C, Aarsland D (2012) Neuropsychiatric symptoms in mild dementia with Lewy bodies and Alzheimer’s disease. Dement Geriatr Cogn Disord 34(1):1–6. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1159/000339590</span><span address="10.1159/000339590" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Donaghy PC, Ciafone J, Durcan R, Hamilton CA, Barker S, Lloyd J et al (2022) Mild cognitive impairment with Lewy bodies: neuropsychiatric supportive symptoms and cognitive profile. Psychol Med 52(6):1147–1155. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1017/S0033291720002901</span><span address="10.1017/S0033291720002901" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Dissanayaka NN, Sellbach A, Silburn PA, O&#x27;Sullivan JD, Marsh R, Mellick GD (2011) Factors associated with depression in Parkinson&#x27;s disease. J Affect Disord 132(1–2):82–88. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/j.jad.2011.01.021</span><span address="10.1016/j.jad.2011.01.021" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Eglit GM, Lopez F, Schiehser DM, Pirogovsky-Turk E, Litvan I, Lessig S et al (2021) Delineation of apathy subgroups in Parkinson&#x27;s disease: differences in clinical presentation, functional ability, health‐related quality of life, and caregiver burden. Mov Disord Clin Pract 8(1):92–99. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mdc3.13127</span><span address="10.1002/mdc3.13127" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Heimrich KG, Schönenberg A, Mendorf S, Moussaoui J, Prell T (2024) An examination of anxiety and its influence on health-related quality of life in Parkinson’s disease using the geriatric anxiety scale: a cross-sectional study. BMC Geriatr 24(1):298. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1186/s12877-024-04911-8</span><span address="10.1186/s12877-024-04911-8" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Kuhlman GD, Flanigan JL, Sperling SA, Barrett MJ (2019) Predictors of health-related quality of life in Parkinson&#x27;s disease. Parkinsonism Relat Disord 65:86–90. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/j.parkreldis.2019.05.009</span><span address="10.1016/j.parkreldis.2019.05.009" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Van de Beek M, van Steenoven I, van der Zande J, Porcelijn I, Barkhof F, Stam C et al (2021) Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. Alzheimers Res Ther 13(1):53. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1186/s13195-021-00792-w</span><span address="10.1186/s13195-021-00792-w" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Breitve MH, Brønnick K, Chwiszczuk LJ, Hynninen MJ, Aarsland D, Rongve A (2018) Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. Alzheimers Res Ther 10(1):83. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1186/s13195-018-0416-5</span><span address="10.1186/s13195-018-0416-5" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Breitve MH, Hynninen MJ, Brønnick K, Chwiszczuk LJ, Auestad BH, Aarsland D et al (2016) A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer’s disease. Alzheimers Res Ther 8(1):3. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1186/s13195-016-0171-4</span><span address="10.1186/s13195-016-0171-4" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Dissanayaka NN, Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK et al (2017) Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson&#x27;s disease. Parkinsonism Relat Disord 36:63–68. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/j.parkreldis.2017.01.001</span><span address="10.1016/j.parkreldis.2017.01.001" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Wyman-Chick KA, O’Keefe LR, Weintraub D, Armstrong MJ, Rosenbloom M, Martin PK et al (2022) Prodromal dementia with Lewy bodies: evolution of symptoms and predictors of dementia onset. J Geriatr Psychiatry Neurol 35(4):527–534. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1177/08919887211023586</span><span address="10.1177/08919887211023586" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Dujardin K, Sockeel P, Delliaux M, Destée A, Defebvre L (2009) Apathy may herald cognitive decline and dementia in Parkinson&#x27;s disease. Mov Disord 24(16):2391–2397. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.22843</span><span address="10.1002/mds.22843" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Jones JD, Kurniadi NE, Kuhn TP, Szymkowicz SM, Bunch J, Rahmani E (2019) Depressive symptoms precede cognitive impairment in de novo Parkinson’s disease patients: Analysis of the PPMI cohort. Neuropsychology 33(8):1111. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1037/neu0000583</span><span address="10.1037/neu0000583" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Den Brok MG, van Dalen JW, van Gool WA, van Moll EP, de Bie RM, Richard E (2015) Apathy in Parkinson&#x27;s disease: a systematic review and meta-analysis. Mov Disord 30(6):759–769. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.26208</span><span address="10.1002/mds.26208" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Dissanayaka NN, Sellbach A, Matheson S, O&#x27;Sullivan JD, Silburn PA, Byrne GJ et al (2010) Anxiety disorders in Parkinson&#x27;s disease: prevalence and risk factors. Mov Disord 25(7):838–845. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.22833</span><span address="10.1002/mds.22833" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Lee DR, McKeith I, Mosimann U, Ghosh-Nodyal A, Thomas AJ (2013) Examining carer stress in dementia: the role of subtype diagnosis and neuropsychiatric symptoms. Int J Geriatr Psychiatry 28(2):135–141. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/gps.3799</span><span address="10.1002/gps.3799" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Liu S, Liu J, Wang X-D, Shi Z, Zhou Y, Li J et al (2018) Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer&#x27;s disease. Int Psychogeriatr 30(8):1131–1138. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1017/S1041610217002630</span><span address="10.1017/S1041610217002630" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Alzahrani H, Venneri A (2015) Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson&#x27;s disease: A systematic review. J Neurol Sci 356(1–2):32–44. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/j.jns.2015.06.037</span><span address="10.1016/j.jns.2015.06.037" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Wen MC, Chan LL, Tan LC, Tan EK (2016) Depression, anxiety, and apathy in Parkinson&#x27;s disease: insights from neuroimaging studies. Eur J Neurol 23(6):1001–1019. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1111/ene.13002</span><span address="10.1111/ene.13002" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX et al (2017) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 16(1):55–65. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/S1474-4422(16)30291-5</span><span address="10.1016/S1474-4422(16)30291-5" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Okkels N, Grothe MJ, Taylor J-P, Hasselbalch SG, Fedorova TD, Knudsen K et al (2024) Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes. Brain 147(7):2308–2324. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1093/brain/awae069</span><span address="10.1093/brain/awae069" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Irwin DJ, Hurtig HI (2018) The contribution of tau, amyloid-beta and alpha-synuclein pathology to dementia in Lewy body disorders. J Alzheimers Dis Parkinsonism 8(4):444. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.4172/2161-0460.1000444</span><span address="10.4172/2161-0460.1000444" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Carey G, Görmezoğlu M, de Jong JJ, Hofman PA, Backes WH, Dujardin K et al (2021) Neuroimaging of anxiety in Parkinson&#x27;s disease: a systematic review. Mov Disord 36(2):327–339. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.28404</span><span address="10.1002/mds.28404" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Sharp SI, Ballard CG, Ziabreva I, Piggott MA, Perry RH, Perry EK et al (2008) Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson’s disease dementia. Dement Geriatr Cogn 26(4):330–338. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1159/000161058</span><span address="10.1159/000161058" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Patterson L, Rushton SP, Attems J, Thomas AJ, Morris CM (2019) Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders. Brain Pathol 29(4):544–557. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1111/bpa.12697</span><span address="10.1111/bpa.12697" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF et al (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP‐CIT SPECT study. Mov Disord 24(14):2097–2103. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.22702</span><span address="10.1002/mds.22702" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Fischer NM, Hinkle JT, Perepezko K, Bakker CC, Morris M, Broen MP et al (2021) Brainstem pathologies correlate with depression and psychosis in Parkinson&#x27;s disease. Am J Geriatr Psychiatry 29(9):958–968. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/j.jagp.2020.12.009</span><span address="10.1016/j.jagp.2020.12.009" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Bohnen N, Kaufer D, Hendrickson R, Constantine G, Mathis C, Moore R (2007) Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry 78(6):641–643. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/j.bbr.2009.12.048</span><span address="10.1016/j.bbr.2009.12.048" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson&#x27;s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(6):1314–1322. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1093/brain/awh445</span><span address="10.1093/brain/awh445" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Maillet A, Krack P, Lhommée E, Météreau E, Klinger H, Favre E et al (2016) The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain 139(9):2486–2502. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1093/brain/aww162</span><span address="10.1093/brain/aww162" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Conio B, Martino M, Magioncalda P, Escelsior A, Inglese M, Amore M et al (2020) Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders. Mol Psychiatry 25(1):82–93. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1038/s41380-019-0406-4</span><span address="10.1038/s41380-019-0406-4" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Drevets WC, Savitz J, Trimble M (2008) The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 13(8):663. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1017/s1092852900013754</span><span address="10.1017/s1092852900013754" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Hu X, Song X, Li E, Liu J, Yuan Y, Liu W et al (2015) Altered resting-state brain activity and connectivity in depressed Parkinson’s disease. PLoS ONE 10(7):e0131133. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1371/journal.pone.0131133</span><span address="10.1371/journal.pone.0131133" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Dan R, Růžička F, Bezdicek O, Růžička E, Roth J, Vymazal J et al (2017) Separate neural representations of depression, anxiety and apathy in Parkinson’s disease. Sci Rep 7(1):12164. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1038/s41598-017-12457-6</span><span address="10.1038/s41598-017-12457-6" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Gliaudelytė L, Rushton SP, Berlinguer-Palmini R, Thomas AJ, Morris CM (2025) Dopaminergic changes in the subgenual cingulate cortex in dementia with lewy bodies associates with presence of depression. Transl Psychiatry 15(1):89. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1038/s41398-025-03298-3</span><span address="10.1038/s41398-025-03298-3" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P (2015) Apathy in Parkinson&#x27;s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 14(5):518–531. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/S1474-4422(15)00019-8</span><span address="10.1016/S1474-4422(15)00019-8" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Jellinger KA, Korczyn AD (2018) Are dementia with Lewy bodies and Parkinson&#x27;s disease dementia the same disease? BMC Med 16(1):34. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1186/s12916-018-1016-8</span><span address="10.1186/s12916-018-1016-8" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Weintraub D (2023) What&#x27;s in a name? The time has come to unify Parkinson&#x27;s disease and dementia with Lewy bodies. Mov Disord 38(11):1977–1981. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.29590</span><span address="10.1002/mds.29590" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Power JH, Barnes OL, Chegini F (2017) L ewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson&#x27;s Disease and Dementia with Lewy Bodies. Brain Pathol 27(1):3–12. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1111/bpa.12344</span><span address="10.1111/bpa.12344" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci 95(11):6469–6473. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1073/pnas.95.11.6469</span><span address="10.1073/pnas.95.11.6469" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson&#x27;s disease. Mov Disord 30(12):1591–1601. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.26424</span><span address="10.1002/mds.26424" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson&#x27;s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27(3):349–356. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.24893</span><span address="10.1002/mds.24893" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H et al (2020) Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 94(17):743–755. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1212/WNL.0000000000009323</span><span address="10.1212/WNL.0000000000009323" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE (2014) The spectrum of cognitive impairment in Lewy body diseases. Mov Disord 29(5):608–621. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.25866</span><span address="10.1002/mds.25866" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1136/bmj.n71</span><span address="10.1136/bmj.n71" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Kasanuki K, Iseki E, Ota K, Kondo D, Ichimiya Y, Sato K, Arai H (2017) 123I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 44(3):358–365. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1007/s00259-016-3466-6</span><span address="10.1007/s00259-016-3466-6" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Mazère J, Lamare F, Allard M, Fernandez P, Mayo W (2017) 123I-Iodobenzovesamicol SPECT Imaging of Cholinergic Systems in Dementia with Lewy Bodies. J Nucl Med 58(1):123–128. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.2967/jnumed.116.176180</span><span address="10.2967/jnumed.116.176180" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Siepel F, Dalen I, Grüner R, Booij J, Brønnick K, Buter T et al (2016) Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies. Mov Disord 31(1):118–125. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.26327</span><span address="10.1002/mds.26327" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Yoo H, Lee S, Chung S, Lee Y, Ye B, Sohn Y et al (2020) Clinical and striatal dopamine transporter predictors of β-amyloid in dementia with Lewy bodies. Neurology 94(13):e1344–e52. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1212/WNL.0000000000009168</span><span address="10.1212/WNL.0000000000009168" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Sturchio A, Svensson JE, Tiger M, Morén AF, Varrone A, Svenningsson P et al (2025) [18F] FE-PE2I PET is a diagnostic tool in dementia with Lewy bodies. PCN Rep 4(2):e70123. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/pcn5.70123</span><span address="10.1002/pcn5.70123" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Almeida O, Burton E, McKeith I, Gholkar A, Burn D, O&#x27;Brien J (2003) MRI study of caudate nucleus volume in Parkinson&#x27;s disease with and without dementia with Lewy bodies and Alzheimer&#x27;s disease. Dement Geriatr Cogn Disord 16(2):57–63. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1159/000070676</span><span address="10.1159/000070676" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Chang Y, Lu C, Wu M, Hsu S, Huang C, Chang W et al (2017) Salience Network and Depressive Severities in Parkinson&#x27;s Disease with Mild Cognitive Impairment: A Structural Covariance Network Analysis. Front Aging Neurosc 9:417. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.3389/fnagi.2017.00417</span><span address="10.3389/fnagi.2017.00417" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Jaramillo-Jimenez A, Giil L, Tovar-Rios D, Borda M, Ferreira D, Brønnick K et al (2021) Association Between Amygdala Volume and Trajectories of Neuropsychiatric Symptoms in Alzheimer&#x27;s Disease and Dementia With Lewy Bodies. Front Neurol 12:679984. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.3389/fneur.2021.679984</span><span address="10.3389/fneur.2021.679984" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Querry M, Botzung A, Cretin B, Demuynck C, Muller C, Ravier A et al Neuroanatomical substrates of depression in dementia with Lewy bodies and Alzheimer’s disease. GeroScience. 2024:1–20. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1007/s11357-024-01190-4</span><span address="10.1007/s11357-024-01190-4" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Xing Y, Fu S, Li M, Ma X, Liu M, Liu X et al (2021) Regional neural activity changes in Parkinson&#x27;s disease-associated mild cognitive impairment and cognitively normal patients. Neuropsychiatr Dis Treat 17. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.2147/NDT.S323127</span><span address="10.2147/NDT.S323127" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Zhang P, Rong S, He C, Li Y, Li X, Chen Z et al (2023) Cortical connectivity of cholinergic basal forebrain in Parkinson&#x27;s disease with mild cognitive impairment. Quant Imaging Med Surg 13(4):2167–2182. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.21037/qims-22-582</span><span address="10.21037/qims-22-582" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Querry M, Botzung A, Sourty M, Chabran E, Sanna L, Loureiro de Sousa P et al (2025) Functional Connectivity Changes Associated With Depression in Dementia With Lewy Bodies. Int J Geriatr Psychiatry 40(3):e70058. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/gps.70058</span><span address="10.1002/gps.70058" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Wright LM, Donaghy PC, Burn DJ, Taylor J-P, T O’Brien J, Yarnall AJ et al (2025) Brain network connectivity underlying neuropsychiatric symptoms in prodromal Lewy body dementia. Neurobiol Aging. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/j.neurobiolaging.2025.04.007</span><span address="10.1016/j.neurobiolaging.2025.04.007" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Gan J, Shi Z, Zuo C, Zhao X, Liu S, Chen Y et al (2023) Analysis of positron emission tomography hypometabolic patterns and neuropsychiatric symptoms in patients with dementia syndromes. CNS Neurosci Ther 29(8):2193–2205. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1111/cns.14169</span><span address="10.1111/cns.14169" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Murayama T, Kobayashi S, Ishida T, Utsumi K, Kawanishi C (2022) Associations Between Regional Cerebral Blood Flow and Psychiatric Symptoms in Dementia With Lewy Bodies Without Parkinsonism. Am J Alzheimers Dis Other Deme 37:15333175221075109. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1177/15333175221075109</span><span address="10.1177/15333175221075109" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Palermo G, Tommasini L, Aghakhanyan G, Frosini D, Giuntini M, Tognoni G et al (2019) Clinical correlates of cerebral amyloid deposition in Parkinson&#x27;s disease dementia: Evidence from a PET study. J Alzheimers Dis 70(2):597–609. <span class="ExternalRef"><span class="RefSource">https://dx.doi.org/10.3233/JAD-190323</span><span address="10.3233/JAD-190323" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Zhang D, Zhou L, Lu C, Feng T, Liu J, Wu T (2024) Free-Water Imaging of the Nucleus Basalis of Meynert in Patients With Idiopathic REM Sleep Behavior Disorder and Parkinson Disease. Neurology 102(7):e209220. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1212/WNL.0000000000209220</span><span address="10.1212/WNL.0000000000209220" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12):2308. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1212/wnl.44.12.2308</span><span address="10.1212/wnl.44.12.2308" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>van Mierlo TJ, Chung C, Foncke EM, Berendse HW, van den Heuvel OA (2015) Depressive symptoms in Parkinson&#x27;s disease are related to decreased hippocampus and amygdala volume. Mov Disord 30(2):245–252. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.26112</span><span address="10.1002/mds.26112" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Zanigni S, Sambati L, Evangelisti S, Testa C, Calandra-Buonaura G, Manners DN et al (2017) Precuneal thickness and depression in Parkinson disease. Neurodegener Dis 17(2–3):97–102. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1159/000450614</span><span address="10.1159/000450614" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Jellinger KA (2022) The pathobiological basis of depression in Parkinson disease: challenges and outlooks. J Neural Transm 129(12):1397–1418. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1007/s00702-022-02559-5</span><span address="10.1007/s00702-022-02559-5" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA (2015) Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. JAMA Psychiatry 72(6):603–611. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1001/jamapsychiatry.2015.0071</span><span address="10.1001/jamapsychiatry.2015.0071" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Carmon J, Heege J, Necus JH, Owen TW, Pipa G, Kaiser M et al (2020) Reliability and comparability of human brain structural covariance networks. NeuroImage 220:117104. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/j.neuroimage.2020.117104</span><span address="10.1016/j.neuroimage.2020.117104" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Lou Y, Huang P, Li D, Cen Z, Wang B, Gao J et al (2015) Altered brain network centrality in depressed Parkinson&#x27;s disease patients. Mov Disord 30(13):1777–1784. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.26321</span><span address="10.1002/mds.26321" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Wei L, Hu X, Zhu Y, Yuan Y, Liu W, Chen H (2017) Aberrant intra-and internetwork functional connectivity in depressed Parkinson’s disease. Sci Rep 7(1):2568. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1038/s41598-017-02127-y</span><span address="10.1038/s41598-017-02127-y" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Bohnen NI, Albin RL (2011) The cholinergic system and Parkinson disease. Behav Brain Res 221(2):564–573. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1136/jnnp.2006.100073</span><span address="10.1136/jnnp.2006.100073" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Dulawa SC, Janowsky DS (2019) Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. Mol Psychiatry 24(5):694–709. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1038/s41380-018-0219-x</span><span address="10.1038/s41380-018-0219-x" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Prange S, Klinger H, Laurencin C, Danaila T, Thobois S (2022) Depression in patients with Parkinson’s disease: current understanding of its neurobiology and implications for treatment. Drugs Aging 39(6):417–439. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1007/s40266-022-00942-1</span><span address="10.1007/s40266-022-00942-1" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Rektorova I, Biundo R, Marecek R, Weis L, Aarsland D, Antonini A (2014) Grey matter changes in cognitively impaired Parkinson&#x27;s disease patients. PLoS ONE 9(1):e85595. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1371/journal.pone.0085595</span><span address="10.1371/journal.pone.0085595" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64(3):327–337. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1001/archpsyc.64.3.327</span><span address="10.1001/archpsyc.64.3.327" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Le Heron C, Apps M, Husain M (2018) The anatomy of apathy: a neurocognitive framework for amotivated behaviour. Neuropsychologia 118:54–67. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1016/j.neuropsychologia.2017.07.003</span><span address="10.1016/j.neuropsychologia.2017.07.003" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Udo N, Hashimoto N, Toyonaga T, Isoyama T, Oyanagi Y, Narita H et al (2020) Apathy in Alzheimer’s disease correlates with the dopamine transporter level in the caudate nuclei. Dement Geriatr Cogn Dis Extra 10(2):86–93. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1159/000509278</span><span address="10.1159/000509278" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Chatterjee A, Hirsch-Reinshagen V, Moussavi SA, Ducharme B, Mackenzie IR, Hsiung GYR (2021) Clinico‐pathological comparison of patients with autopsy‐confirmed Alzheimer&#x27;s disease, dementia with Lewy bodies, and mixed pathology. Alzheimer&#x27;s Dement: Diagn Assess Dis Monit 13(1):e12189. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/dad2.12189</span><span address="10.1002/dad2.12189" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Jellinger KA, Attems J (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115(4):427–436. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1007/s00401-008-0347-5</span><span address="10.1007/s00401-008-0347-5" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Merdes A, Hansen L, Jeste D, Galasko D, Hofstetter C, Ho G et al (2003) Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60(10):1586–1590. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1212/01.wnl.0000065889.42856.f2</span><span address="10.1212/01.wnl.0000065889.42856.f2" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TL et al (2016) Mood changes in cognitively normal older adults are linked to Alzheimer disease biomarker levels. <em>Am J Geriatr Psychiatry</em>. ;24(11):1095 – 104. https://doi.org/1095-1104.10.1016/j.jagp.2016.04.004</span></li><li><span>Krell-Roesch J, Rakusa M, Syrjanen JA, van Harten AC, Lowe VJ, Jack CR Jr et al (2023) Association between CSF biomarkers of Alzheimer&#x27;s disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. Alzheimers Dement 19(10):4498–4506. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/alz.12557</span><span address="10.1002/alz.12557" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Yasuno F, Minami H, Hattori H, Initiative ADN (2021) Relationship between neuropsychiatric symptoms and Alzheimer&#x27;s disease pathology: An in vivo positron emission tomography study. Int J Geriatr Psychiatry 36(4):598–605. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/gps.5459</span><span address="10.1002/gps.5459" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Hampel H, Mesulam M-M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141(7):1917–1933. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1093/brain/awy132</span><span address="10.1093/brain/awy132" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Buch AM, Liston C (2021) Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics. Neuropsychopharmacology 46(1):156–. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1038/s41386-020-00789-3</span><span address="10.1038/s41386-020-00789-3" targettype="DOI" class="RefTarget"></span></span>.  75</span></li><li><span>Levy R, Dubois B (2006) Apathy and the functional anatomy of the prefrontal cortex–basal ganglia circuits. Cereb Cortex 16(7):916–928. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1093/cercor/bhj043</span><span address="10.1093/cercor/bhj043" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Akiki TJ, Jubeir J, Bertrand C, Tozzi L, Williams LM (2025) Neural circuit basis of pathological anxiety. Nat Rev Neurosci 26(1):5–22. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1038/s41583-024-00880-4</span><span address="10.1038/s41583-024-00880-4" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Burn DJ, Landau S, Hindle JV, Samuel M, Wilson KC, Hurt CS et al (2012) Parkinson&#x27;s disease motor subtypes and mood. Mov Disord 27(3):379–386. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/mds.24041</span><span address="10.1002/mds.24041" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Elder GJ, Colloby SJ, Lett DJ, O&#x27;Brien JT, Anderson KN, Burn DJ et al (2016) Depressive symptoms are associated with daytime sleepiness and subjective sleep quality in dementia with Lewy bodies. Int J Geriatr Psychiatry 31(7):765–770. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1002/gps.4389</span><span address="10.1002/gps.4389" targettype="DOI" class="RefTarget"></span></span></span></li><li><span>Therrien S, Turnbull A, Anthony M, Conwell Y, Lin FV (2023) Influence of affective states on informant impression of neuropsychiatric symptoms in people living with MCI. Aging Ment Health 27(11):2128–2133. <span class="ExternalRef"><span class="RefSource">https://doi.org/10.1080/13607863.2023.2191928</span><span address="10.1080/13607863.2023.2191928" targettype="DOI" class="RefTarget"></span></span></span></li></ol></div></span></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Tables</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><div class="tw-text-base tw-antialiased tw-leading-relaxed tw-text-left tw-text-black md:tw-leading-loose _fulltext-content"><span style="display:block"><div><p>Tables not available with this version.</p></div></span></div></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Additional Declarations</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><p class="tw-text-base tw-antialiased tw-leading-relaxed tw-text-left tw-text-black md:tw-leading-loose _fulltext-content"><span style="display:block"><p>The authors declare no competing interests.</p></span></p></div></div><div class="tw-border-b-2 tw-border-gray-100 tw-px-4"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><button type="button" class="focus:tw-outline-none tw-group tw-min-w-full"><div class="tw-flex tw-items-start tw-justify-between"><div class="tw-py-2 tw-w-full"><h2 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-xl">Supplementary Files</h2></div><div class="tw-py-2 sm:tw-border-r-2 sm:tw-border-white"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-ml-4 tw-h-7 tw-w-7 tw-flex-shrink-0 tw-rounded-full tw-text-gray-500 group-hover:tw-bg-gray-200 group-hover:tw-text-gray-900 tw-transform tw-duration-300 -tw-rotate-180"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-pb-1"><ul class="tw-pl-6 tw-list-disc tw-list-outside"><li class="tw-pb-2 tw-break-words"><a href="https://assets-eu.researchsquare.com/files/rs-7472898/v1/d1e16d24214948eea0db251c.pdf" class="tw-text-blue-600 hover:tw-text-blue-800 hover:tw-underline">Supplemetarymaterial.pdf</a></li></ul></div></div></div></div></div><div class="tw-col-span-4 lg:tw-min-h-screen xl:tw-px-0"><div class="tw-bg-gray-50 md:tw-px-1.5 tw-max-w-reading tw-mx-auto lg:tw-bg-white lg:tw-sticky lg:tw-top-0 lg:tw-flex-1 lg:tw-h-screen lg:tw-overflow-y-scroll lg:tw-overflow-visible lg:tw-mx-0 lg:tw-px-0 lg:tw-max-w-none _rs-scrollbar"><div class="tw-flex tw-w-full lg:tw-justify-end"><div class="tw-pt-6 tw-pb-24 tw-w-full sm:tw-max-w-xl lg:tw-px-4 xl:tw-px-8"><div class="tw-hidden lg:tw-flex tw-pl-3 tw-justify-end"><div class="tw-pr-3"><div class="tw-relative tw-inline-block tw-text-left" data-headlessui-state=""><div><button class="tw-group tw-inline-flex tw-items-center tw-px-3 tw-py-2 tw-transition-all tw-border-2 tw-rounded-md tw-group tw-bg-white tw-border-gray-100 hover:tw-bg-gray-100 focus:tw-outline-none" id="headlessui-menu-button-:R56l6:" type="button" aria-haspopup="menu" aria-expanded="false" data-headlessui-state=""><svg xmlns="http://www.w3.org/2000/svg" class="tw-w-5 tw-h-5 tw-text-gray-600" fill="none" viewBox="0 0 24 24" stroke="currentColor"><path d="M16.6187 6.07577C17.6476 6.07404 18.4714 6.44992 19.09 7.20342C19.6858 7.97982 19.9846 8.89392 19.9864 9.94571C19.9879 10.8146 19.8292 11.6266 19.5103 12.3816C19.1915 13.1367 18.7925 13.8234 18.3134 14.4415C17.8114 15.0597 17.2864 15.5979 16.7385 16.0562C16.1676 16.5373 15.6424 16.9383 15.1628 17.2592C14.6832 17.603 14.2949 17.8552 13.998 18.0158C13.6781 18.1763 13.5296 18.2566 13.5525 18.2566L12.7619 17.1947C12.9675 17.1029 13.2416 16.9195 13.5841 16.6446C13.9266 16.3925 14.2691 16.0832 14.6114 15.7168C14.9309 15.3504 15.2161 14.9498 15.4668 14.5149C15.7177 14.1029 15.8427 13.7026 15.8421 13.3139C15.8417 13.0852 15.7041 12.8568 15.4294 12.6286C15.1546 12.4233 14.857 12.1723 14.5363 11.8756C14.2158 11.6017 13.9179 11.2593 13.6429 10.8482C13.3678 10.4599 13.2298 9.97999 13.2289 9.40837C13.228 8.90534 13.3301 8.44786 13.5352 8.03595C13.7175 7.62407 13.9684 7.26924 14.288 6.97145C14.5848 6.69657 14.9388 6.47875 15.3501 6.318C15.7614 6.15725 16.1843 6.07651 16.6187 6.07577ZM7.29256 6.02144C7.81845 6.02055 8.29881 6.13406 8.73363 6.36198C9.16845 6.58989 9.54624 6.89793 9.86701 7.28609C10.1878 7.67426 10.44 8.1197 10.6238 8.62242C10.7848 9.14805 10.8657 9.7081 10.8667 10.3026C10.8687 11.4916 10.6191 12.5895 10.1178 13.5964C9.5936 14.6262 9.02346 15.5075 8.40734 16.2402C7.67713 17.1103 6.84389 17.9006 5.90763 18.611L4.91144 17.6866C5.11699 17.5491 5.36814 17.3314 5.66488 17.0337C5.93876 16.736 6.20111 16.3811 6.45192 15.9691C6.67992 15.5801 6.88501 15.1681 7.06719 14.7334C7.22651 14.2987 7.30583 13.8756 7.30513 13.464C7.30467 13.1896 7.13279 12.9612 6.78951 12.7789C6.44623 12.5966 6.06857 12.3686 5.65653 12.0949C5.2445 11.8212 4.86663 11.4674 4.52292 11.0336C4.17925 10.6226 4.00678 10.0398 4.00551 9.28526C4.00473 8.82796 4.09548 8.4048 4.27774 8.01579C4.46 7.62677 4.71094 7.28337 5.03055 6.98559C5.32729 6.68784 5.68129 6.44716 6.09255 6.26355C6.48099 6.10283 6.88099 6.02213 7.29256 6.02144Z" stroke="currentColor" fill="currentColor"></path></svg><p class="tw-antialiased tw-hidden tw-ml-2 tw-text-sm tw-font-bold tw-text-gray-700 group-hover:tw-underline md:tw-block lg:tw-hidden xl:tw-block">Cite</p></button></div></div></div><div class="last:tw-pr-0"><div class="tw-relative tw-inline-block tw-text-left" data-headlessui-state=""><div><button class="tw-group tw-inline-flex tw-items-center tw-px-3 tw-py-2 tw-transition-all tw-border-2 tw-rounded-md tw-group tw-bg-white tw-border-gray-100 hover:tw-bg-gray-100 focus:tw-outline-none" id="headlessui-menu-button-:R5ml6:" type="button" aria-haspopup="menu" aria-expanded="false" data-headlessui-state=""><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" aria-hidden="true" class="tw-w-5 tw-h-5 tw-text-gray-600"><path stroke-linecap="round" stroke-linejoin="round" d="M8.684 13.342C8.886 12.938 9 12.482 9 12c0-.482-.114-.938-.316-1.342m0 2.684a3 3 0 110-2.684m0 2.684l6.632 3.316m-6.632-6l6.632-3.316m0 0a3 3 0 105.367-2.684 3 3 0 00-5.367 2.684zm0 9.316a3 3 0 105.368 2.684 3 3 0 00-5.368-2.684z"></path></svg><p class="tw-antialiased tw-hidden tw-ml-2 tw-text-sm tw-font-bold tw-text-gray-700 group-hover:tw-underline md:tw-block lg:tw-hidden xl:tw-block">Share</p></button></div></div></div><a href="https://www.researchsquare.com/article/rs-7472898/v1.pdf?c=1756738163000" target="_blank" rel="noopener noreferrer" class="tw-text-blue-600 hover:tw-text-blue-800 hover:tw-underline tw-inline-flex tw-items-center tw-px-3.5 tw-py-1.5 tw-transition-all tw-border-2 tw-rounded-md tw-group tw-border-blue-50 tw-bg-blue-50 hover:tw-bg-blue-100 hover:tw-border-blue-100 focus:tw-outline-none tw-text-blue-600 hover:tw-text-blue-800 hover:tw-underline tw-ml-3" data-track="content_download" data-track-context="article pdf" data-track-category="Posted" data-track-content-type="Systematic Review" data-track-label="rs-7472898"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" aria-hidden="true" class="tw-w-5 tw-h-5"><path stroke-linecap="round" stroke-linejoin="round" d="M12 10v6m0 0l-3-3m3 3l3-3m2 8H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"></path></svg><span class="tw-antialiased tw-ml-2 tw-text-sm tw-font-bold"><span class="tw-hidden xl:tw-contents">Download</span> PDF</span></a></div><div class="tw-mx-2.5 lg:tw-mx-0 tw-border-2 tw-border-gray-100 tw-bg-white tw-rounded-lg tw-hidden lg:tw-block lg:tw-mt-4"><div class="tw-px-4"><button type="button" class="tw-min-w-full focus:tw-outline-none tw-group"><div class="tw-flex tw-items-center tw-justify-between"><div class="tw-w-full tw-py-2"><div class="tw-flex tw-items-center"><h3 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-base">Status:</h3><div class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700 tw-ml-2"><p class="tw-antialiased tw-text-left tw-text-sm tw-color-gray-800">Posted</p></div></div></div><div class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700 tw-my-2 tw-flex tw-items-center tw-duration-300 tw-transform tw-bg-gray-100 group-hover:tw-bg-gray-200"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black tw-text-gray-800 group-hover:tw-text-gray-900 tw-flex"></p><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" aria-hidden="true" class="tw-text-gray-800 group-hover:tw-text-gray-900 tw-h-6 tw-w-6 tw-flex-shrink-0 tw-rounded-full tw-transform tw-duration-300"><path fill-rule="evenodd" d="M5.293 7.293a1 1 0 011.414 0L10 10.586l3.293-3.293a1 1 0 111.414 1.414l-4 4a1 1 0 01-1.414 0l-4-4a1 1 0 010-1.414z" clip-rule="evenodd"></path></svg></div></div></button></div><div class="tw-px-4 tw-border-t-2 tw-border-gray-100"><div class="tw-flex tw-items-start tw-justify-between tw-min-w-full"><div class="tw-py-2"><div class="tw-text-left"><h3 class="tw-antialiased tw-font-bold tw-text-left tw-text-blue-900 tw-text-base">Version <!-- -->1</h3><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black tw-text-gray-700">posted<!-- --> </p></div></div></div><div class="tw-pt-1"><div class="tw-pb-1"><p class="tw-antialiased tw-text-left tw-text-sm tw-text-black"><span class="tw-rounded-xl tw-font-bold tw-px-3 tw-py-1 tw-bg-gray-100 tw-text-gray-700 tw-flex tw-justify-center tw-w-full tw-mb-2">You are reading this <!-- -->latest<!-- --> <!-- -->preprint<!-- --> version</span></p></div></div></div></div></div></div></div></div></div></div></div></div></div><div class="original-css"><footer class="section b-pb-60-d b-pb-20-m"><div class="tw-justify-between tw-block tw-p-4 tw-space-y-6 lg:tw-space-x-6 lg:tw-space-y-0 rs-container lg:tw-flex"><div class="tw-max-w-lg tw-b-mb-20"><a href="/"><img class="logo-rs" src="/static/img/logos/logo-rs.svg" alt="Research Square"/></a><p class="footer-desc b-pb-15">Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal.</p><p class="footer-desc">As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing.</p><div class="icons is-flex b-pt-25 b-pb-20"><a href="https://twitter.com/researchsquare" rel="nofollow"><img src="/static/img/icons/icon-twitter.svg" alt="Twitter logo"/></a><a href="https://www.facebook.com/researchsquare" rel="nofollow"><img src="/static/img/icons/icon-facebook.svg" alt="Facebook logo"/></a><a href="https://www.youtube.com/c/researchsquare" rel="nofollow"><img src="/static/img/icons/icon-youtube.svg" alt="YouTube logo"/></a><a href="https://www.instagram.com/researchsquarecompany/" rel="nofollow"><img src="/static/img/icons/icon-instagram.svg" alt="Instagram logo"/></a><a href="https://www.linkedin.com/company/research-square-co" rel="nofollow"><img src="/static/img/icons/icon-linkedin.svg" alt="LinkedIn logo"/></a></div><div class="researcher-app"><a href="https://www.researcher-app.com/?utm_source=researchsquare&amp;utm_medium=referral&amp;utm_campaign=&amp;utm_content=logo" class="align-m" target="_blank" rel="noopener noreferrer"><h6 class="color-text-90 b-pr-10">Also discoverable on</h6><img src="/static/img/logos/logo-researcher-app.svg" alt="ResearcherApp logo"/></a></div></div><div class="tw-justify-between tw-block tw-space-y-6 lg:tw-space-x-6 lg:tw-space-y-0 lg:tw-flex"><div id="platform"><h5 class="caps color-text-b4 b-mt-3 b-pb-15 b-mr-40-d">Platform</h5><p class="footer-link"><a href="/researchers/preprints">About</a></p><p class="footer-link"><a href="/about">Our Team</a></p><p class="footer-link"><a href="/researchers/in-review">In Review</a></p><p class="footer-link"><a href="/legal/editorial">Editorial Policies</a></p><p class="footer-link"><a href="/advisory-board">Advisory Board</a></p><p class="footer-link"><a target="_blank" rel="noopener noreferrer" data-track="click_contact_us_button" data-track-context="Contact us button click footer help center" href="https://support.researchsquare.com">Help Center</a></p></div><div id="resources"><h5 class="caps color-text-b4 b-mt-3 b-pb-15 b-mr-20-d">Resources</h5><p class="footer-link"><a href="/researchers">Author Services</a></p><p class="footer-link"><a href="/research-quality-evaluation">Research Quality Evaluation</a></p><p class="footer-link"><a href="/accessibility">Accessibility</a></p><p class="footer-link"><a href="/request-api">API Access</a></p><p class="footer-link"><a href="/rss.xml" rel="alternate" type="application/rss+xml">RSS feed</a></p><p class="footer-link"><button data-cc-action="preferences">Manage Cookie Preferences</button></p></div></div></div></footer><footer class="section columns tail"><div class="column is-narrow is-paddingless"><div class="navbar"><p class="navbar-item">© Research Square <!-- -->2025<!-- --> | ISSN 2693-5015 (online)<!-- --> </p><a class="navbar-item" href="/legal/privacy">Privacy Policy</a><a class="navbar-item" href="/legal/terms-of-service">Terms of Service</a><a class="navbar-item" href="/legal/do-not-sell-my-personal-information">Do Not Sell My Personal Information</a></div></div></footer></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"initialData":{"identity":"rs-7472898","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":506454951,"identity":"454cfce1-7d15-48b2-981a-2b5c033163e7","order_by":0,"name":"Naomi Mullis","email":"","orcid":"","institution":"Newcastle University","correspondingAuthor":false,"prefix":"","firstName":"Naomi","middleName":"","lastName":"Mullis","suffix":""},{"id":506454731,"identity":"8bb559e8-4d5f-4c0d-9aa5-1ded0c6d50b7","order_by":1,"name":"Laura M Wright","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABKElEQVRIie2RsWrDMBCGTwTcRUSrhkJewUJQCCTtq0gY0sWmQ5YMhaoYlCXFq/IQBUOWjgZDs/gBCl1cCs1iiscWQlMnwdCAAhk76Ft0N3y6+yUAh+Mf0m0LDzBA3Xbl/ujYFO+Pgu7NvkZKnKJAo8T4JOWsuKi/IL/pksfl+/BpIJPpclWKCfSIwty3KTjk8xnkfU0/ZRwVI2mKkClRADMZ5sK6WMib4K++RwsWRzqPUgiRkhpQCphnNoVUHK1bpa83UUpWb0r+wNVRhYa8s5tCZixGOotSKpiSCuRWsS5GP8adc3/TTMFs/qCDO/NSMSOeaWByb2yLT0iwQNVk5PeSwq+/9SUnyXVZ17eDYTKNF9T2yju2l9HDJeiRXzmYZ4vqcDgcjoZfwnld1OPbbHQAAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0002-0558-7811","institution":"Newcastle University","correspondingAuthor":true,"prefix":"","firstName":"Laura","middleName":"M","lastName":"Wright","suffix":""}],"badges":[],"createdAt":"2025-08-27 15:04:05","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-7472898/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7472898/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":90318383,"identity":"2d360f62-0e0a-42f6-9853-25b3fd57d81b","added_by":"auto","created_at":"2025-09-01 10:33:22","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":404957,"visible":true,"origin":"","legend":"","description":"","filename":"MullisWrightJoN.docx","url":"https://assets-eu.researchsquare.com/files/rs-7472898/v1/a5cde939a5558c0df3ccfa1b.docx"},{"id":90318376,"identity":"ef025c42-c82b-4849-b57a-ba0698557614","added_by":"auto","created_at":"2025-09-01 10:33:22","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":342,"visible":true,"origin":"","legend":"","description":"","filename":"rs7472898.json","url":"https://assets-eu.researchsquare.com/files/rs-7472898/v1/60fdcb887f4b11f062a0c2fd.json"},{"id":90319928,"identity":"dacc7d62-2420-4113-acc7-bd24ab8690ac","added_by":"auto","created_at":"2025-09-01 10:41:22","extension":"xml","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":212800,"visible":true,"origin":"","legend":"","description":"","filename":"rs74728980enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7472898/v1/a7e78d2f2c8563d34d184d36.xml"},{"id":90319927,"identity":"2c3bc70f-0c86-40db-849c-de08426ba560","added_by":"auto","created_at":"2025-09-01 10:41:22","extension":"png","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":150192,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7472898/v1/7c9086c74aad123480d9d21f.png"},{"id":90318378,"identity":"67e83820-5d46-4fe3-b010-2e326b630d48","added_by":"auto","created_at":"2025-09-01 10:33:22","extension":"png","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":55568,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7472898/v1/a333bd88f6fe83e29e532dfe.png"},{"id":90318386,"identity":"89a7bf35-80a7-4ed2-a2e1-0e7dc102e214","added_by":"auto","created_at":"2025-09-01 10:33:22","extension":"xml","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":210158,"visible":true,"origin":"","legend":"","description":"","filename":"rs74728980structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7472898/v1/e1d774d8ad3607e8f6f2d605.xml"},{"id":90318384,"identity":"27eacda3-8f88-4ca4-ba57-02daa2e8b191","added_by":"auto","created_at":"2025-09-01 10:33:22","extension":"html","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":224411,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7472898/v1/40b335b52293dbf213a6add2.html"},{"id":90318379,"identity":"c3437ed3-56c7-40f7-863c-c649400cd6a6","added_by":"auto","created_at":"2025-09-01 10:33:22","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":849287,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eFlow chart and research procedure of the systematic review\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAS, Affective symptoms; LBD, Lewy body disease\u003c/p\u003e","description":"","filename":"Fig.1.PrismaFlowchart.png","url":"https://assets-eu.researchsquare.com/files/rs-7472898/v1/59c905d2c2bb7fc66b5bfd2e.png"},{"id":90320684,"identity":"d9bce039-0a59-4416-b74b-0c84e22e2df7","added_by":"auto","created_at":"2025-09-01 10:49:23","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1274075,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7472898/v1/d61e3cd9-87e4-4cfa-b2b0-5cc85cda977a.pdf"},{"id":90318381,"identity":"3bc5c7c4-002b-4b7c-95ba-e83598d88aee","added_by":"auto","created_at":"2025-09-01 10:33:22","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":636393,"visible":true,"origin":"","legend":"","description":"","filename":"Supplemetarymaterial.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7472898/v1/d1e16d24214948eea0db251c.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003eNeuroimaging of affective symptoms in Lewy body dementia: A systematic review\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eLewy body diseases (LBDs), including Parkinson’s disease (PD), PD dementia (PDD) and dementia with Lewy bodies (DLB), are the second leading cause of neurodegenerative dementia after Alzheimer’s Disease (AD) [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Clinical features of LBDs can include parkinsonian motor symptoms, cognitive decline and neuropsychiatric symptoms such as visual hallucinations, and sleep disorders [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Alongside core features, LBDs are typically accompanied by a high volume of supportive symptoms that add to clinical complexity. Affective symptoms, namely anxiety, apathy and depression, are common and debilitating supportive features of LBDs [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Such symptoms are highly prevalent in neurodegenerative conditions [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e] and particularly common in PDD and DLB when compared with other dementia subtypes [\u003cspan additionalcitationids=\"CR7\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e–\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Furthermore, anxiety, apathy and depression in LBD have been identified as some of the primary symptoms associated with reductions in quality of life [\u003cspan additionalcitationids=\"CR10 CR11 CR12\" citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e–\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e] and increases in cognitive decline [\u003cspan additionalcitationids=\"CR15 CR16 CR17 CR18\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e–\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e], motor symptom severity [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e], and caregiver burden [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eDespite their prevalence, the underlying mechanisms of affective symptoms in LBD remain poorly understood. Moreover, most research examining the neural correlates of neuropsychiatric symptoms in LBD has been conducted primarily in cognitively healthy PD, excluding the cognitively impaired LBD groups that these symptoms most frequently affect [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. This exemption of cognitively impaired cohorts from the literature is of particular significance given the established pathophysiological differences between cognitively healthy PD, at one end of the LBD spectrum, and the dementia syndromes of PDD and DLB at the other, which may include a greater burden of AD co-pathology and a more severe cholinergic degeneration [\u003cspan additionalcitationids=\"CR27\" citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e–\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. Given the well-established association between affective symptoms and cognitive decline [\u003cspan additionalcitationids=\"CR15 CR16\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e–\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e], the relative paucity of research in Lewy body dementias (PDD and DLB) represents a distinct gap in the literature.\u003c/p\u003e\u003cp\u003ePrevious reviews of neuroimaging studies conducted in cognitively healthy PD have revealed multiple structural and functional brain changes associated with apathy, depression and anxiety [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e] and despite a paucity of neuroimaging studies in DLB, neurochemical and neuropathological research has revealed similar associations between affective symptoms and neurotransmission pathways in both PD and DLB [\u003cspan additionalcitationids=\"CR31 CR32 CR33 CR34 CR35\" citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e–\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]. In the wider psychiatric literature, affective states related to psychiatric disorders have been postulated to result from specific changes in functional connectivity both within and between intrinsic resting-state networks relating to impairments in neurotransmission, such as those characteristic of LBDs [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e]. Moreover, converging evidence suggesting that certain brain regions, such as the subgenual anterior cingulate cortex, play a significant role in mood disorders [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e], has similarly been reflected in neuroimaging studies of such symptoms in cognitively healthy PD and neuropathological studies of DLB [\u003cspan additionalcitationids=\"CR40\" citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e–\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e]. Neural correlates of anxiety and apathy have shown similar convergence across psychiatric and PD literature, suggesting that LBDs may exacerbate mechanisms underlying affective symptoms, resulting in an increased prevalence among these patient groups [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. What remains unclear however, are the specific neuropathological changes contributing to the increased severity and prevalence of affective symptoms in the context of cognitive decline.\u003c/p\u003e\u003cp\u003eAlthough DLB and PDD are may be considered two clinically distinct entities, the historical debate regarding their nosological distinction is ongoing [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e, \u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Both DLB and PDD are underpinned by similar pathophysiological processes [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e] and clinical profiles [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e] to the extent that both may be preceded by a prodromal period of mild cognitive impairment (MCI) [\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e]. In clinical practice, a rather arbitrary ‘one year rule’ defines PDD based on the initial appearance of motor symptoms at least one year prior to cognitive decline, although no symptoms definitively distinguish PDD from DLB at the dementia stages [\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. The present review therefore examines the PDD and DLB literature in aggregate, including studies of prodromal MCI groups, to synthesise current evidence regarding neural correlates of affective symptoms across the spectrum of Lewy body dementias.\u003c/p\u003e\u003cp\u003eThe aim of this review is to identify brain regions involved in affective symptoms in Lewy body dementias based on anatomical, functional, metabolic and neurotransmitter imaging studies. Moreover, we aim to provide information on how these neural correlates may differ across symptom type, disease stage and disease subtype. Finally, we aim to inform the methods of prospective neuroimaging studies seeking to investigate the neural basis of affective symptoms in these disease groups.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eThe review protocol for the current systematic review was registered in PROSPERO following PRISMA guidelines (PROSPERO ID CRD42024539741) [\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e]. The review protocol can be accessed here: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.crd.york.ac.uk/PROSPERO/view/CRD42024539741\u003c/span\u003e\u003cspan address=\"https://www.crd.york.ac.uk/PROSPERO/view/CRD42024539741\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Literature searches were conducted in PubMed, PsychINFO and Web of Science Core Collection. The search terms used included terms related to Parkinson’s OR Lewy bodies OR synucleinopathies AND cognitive impairment OR cognitive decline OR cognitive complaint OR dementia AND imaging (magnetic resonance imaging, positron emission tomography, single photon emission computed tomography, diffusion tensor imaging etc.) AND apathy OR anxiety OR depression OR affective disorder OR mood disorder. A detailed list of search terms is available in \u003cb\u003eTable S1\u003c/b\u003e. The search was not limited by date so all studies available until the date of the search (15th July 2025) were included. These searches resulted in the identification of 1841 articles.\u003c/p\u003e\u003cp\u003eFollowing the removal of duplicates, 1315 articles were included in title and abstract screening. Inclusion criteria required that studies must include the following: participants with a diagnosis of LBD (either PD or DLB) with evidence of cognitive impairment; an assessment of anxiety, apathy or depression; any method of neuroimaging with outcomes including grey matter volume, cortical thickness, white matter microstructural integrity, blood-oxygen-level-dependent signal (or network connectivity strength), glucose metabolism or binding-ratio values; a categorical comparison between patients with and without anxiety, apathy or depression on imaging parameters or a correlation of imaging parameters with the severity of the neuropsychiatric symptom as a continuous variable. Exclusion criteria included: foreign language articles for which an English translation was unavailable; review articles reporting no original data; studies focused on diseases other than PD or DLB (including other synucleinopathies); studies that did not include a cognitively impaired participant group or that pooled cognitively unimpaired and impaired groups for imaging analysis; studies that did not utilise standard diagnostic criteria for cognitive impairment or LBD; studies without any assessments of anxiety, apathy or depression; studies without neuroimaging; studies that did not analyse anxiety, apathy or depression in relation to neuroimaging outcomes and studies in which the neuroimaging outcomes were not regionally quantified (e.g., amyloid-positive PET vs amyloid-negative).\u003c/p\u003e\u003cp\u003eEligibility was determined independently by two researchers (L.W. and N.M.). Any discrepancies were discussed until a consensus could be reached. Following title and abstract screening, 142 articles were sourced for full text screening. Full details of the article screening process can be found in \u003cb\u003eFig.\u0026nbsp;1\u003c/b\u003e.\u003c/p\u003e\u003cp\u003eData extraction and quality assessment were carried out by two researchers (L.W. and N.M.). A data extraction sheet included manuscript details (authors, title, year of publication and journal), demographic data (sample size, age, gender, disease duration, education, medication, global cognitive function), neuropsychiatric scales and scores and details of neuroimaging (methods, outcome measures and findings). Peak coordinates and effect size measures for regions found to have a significant relationship with affective symptom severity were also collected where possible. Demographic data were recorded in two separate tables for PDD and DLB groups. Similarly, imaging data and results were recorded in two separate tables for PDD and DLB groups.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eEighteen imaging studies met the inclusion criteria and were included for systematic review. Figure\u0026nbsp;1 outlines the study selection procedure. Of the studies included, six utilized neurotransmitter/transporter imaging methods [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e, \u003cspan additionalcitationids=\"CR53 CR54 CR55\" citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e–\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e], four were anatomical MRI studies [\u003cspan additionalcitationids=\"CR58 CR59\" citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e–\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e], four utilized resting-state functional MRI (fMRI) [\u003cspan additionalcitationids=\"CR62 CR63\" citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e–\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e], one was a metabolic imaging study [\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e], one measured regional cerebral blood flow [\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e], one examined amyloid (Aβ) PET [\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e] and one utilized diffusion tensor imaging [\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e]. Of the studies, seventeen included a measure of depression, eight included a measure of anxiety and seven included a measure of apathy. Combined, the included studies involved 785 participants with Lewy body related cognitive impairment including: DLB or MCI with Lewy bodies (MCI-LB) (n = 492) and PDD or PD related MCI (PD-MCI) (n = 293). \u003cb\u003eTables\u0026nbsp;1\u003c/b\u003e and \u003cb\u003e2\u003c/b\u003e outline the demographic data of PDD or PD-MCI and DLB or MCI-LB groups, respectively. According to the quality assessment, nine studies received a score of “good,” and nine received a score of “moderate.” Further information about this quality assessment can be found in the Supplementary Material. Given the limited number of studies and the heterogeneity between them, meta-analysis was not possible and therefore only a narrative synthesis of the results is provided.\u003c/p\u003e\u003cp\u003e\u003cb\u003e-Please insert Tables\u0026nbsp;1 and 2 about here-\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eAnatomical MRI Studies\u003c/em\u003e\u003c/p\u003e\u003cp\u003eTogether, the four anatomical MRI studies comprised 28 participants diagnosed with PD with normal cognition (PD-NC), 77 with PD-MCI, 20 with PDD, 117 with DLB, 119 with AD and 53 healthy controls (HC). Two of the studies, by Chang et al. ([\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e] and Querry et al. [\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e], were based on 3-T MRI T1-weighted scans. The remaining two, by Jaramillo-Jimenez et al.[\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e] and Almeida et al.[\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e], were based on 1.5-T MRI T1-weighted scans. Two studies analysed grey matter volume using a region of interest approach [\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e, \u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e] and two used voxel-based morphometry [\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e, \u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e]. Chang et al. [\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e] additionally implemented a structural covariance analysis to analyse structural connectivity. Three of the four studies assessed depression; two in PDD or PD-MCI groups using the Geriatric Depression Scale (GDS) [\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e, \u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e] and one in DLB and AD participants using the Mini International Neuropsychiatric Interview (MINI) [\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e]. The study by Jaramillo-Jimenez et al. [\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e] assessed a range of neuropsychiatric symptoms in participants with AD and DLB, using the 12 items of the Neuropsychiatric Inventory (NPI) [\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe study by Almeida et al. (2003) found no association between caudate volume and depression in their PDD group. In their whole-brain voxel-based morphometry analysis, Chang et al., (2017) found PD-MCI patients with depression to have greater grey matter volume in the right fusiform gyrus, right hippocampus and bilateral superior parietal gyri than those without. In the fronto-insula, however, those with depression had lower grey matter volume. GDS scores were also found to positively correlate with volume in the right fusiform gyrus and the left superior parietal lobe and negatively correlate with volume in the right fronto-insula and the left lingual gyrus. Finally, eight clusters including the left anterior cingulate, left calcarine, left caudate, right hippocampus, right inferior frontal gyrus, left lingual gyrus, left rolandic operculum, and right superior frontal lobe demonstrated stronger structural covariance with the right fronto-insula cortex in the non-depressed than in the depressed PD-MCI group. Results from all studies involving PDD or PD-MCI groups can be found in \u003cb\u003eTable\u0026nbsp;3\u003c/b\u003e.\u003c/p\u003e\u003cp\u003eOf the two studies that included DLB groups, the study by Querry et al., (2024) found that DLB patients classified as depressed had lower grey matter volume in right middle frontal and posterior cingulate regions than those without depression [\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e]. Whereas, the study by Jaramillo-Jimenez et al. (2021) found no association between amygdala volume and longitudinal development of affective symptoms in DLB. Results for DLB studies are presented in \u003cb\u003eTable\u0026nbsp;4\u003c/b\u003e.\u003c/p\u003e\u003cp\u003e\u003cb\u003e-Please insert Tables\u0026nbsp;3 and 4 about here-\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cem\u003eFunctional MRI Studies\u003c/em\u003e\u003c/p\u003e\u003cp\u003eFour out of the 18 studies examined neuropsychiatric symptoms in LBD using fMRI [\u003cspan additionalcitationids=\"CR62 CR63\" citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e–\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e].  Three studies included participants with PD-MCI and two included participants with MCI-LB or DLB amounting to a total of 83 PD-MCI, 61 PD-NC, 28 MCI-LB, 66 DLB and 54 HC across studies. All studies utilized a 3T MRI scanner. Wright et al. [\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e] utilized the NPI to evaluate apathy and depression (as a composite affective disorder factor) and anxiety. The studies by Xing et al. [\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e] and Zhang et al. [\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e] used the Hamilton Depression Rating Scale (HAMD) and the Hamilton Anxiety Rating Scale (HAMA) to evaluate depression and anxiety symptoms. The study by Querry et al. [\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e] used the MINI to evaluate depression.\u003c/p\u003e\u003cp\u003eEach study used slightly different outcome measures. The study by Xing et al. [\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e] assessed regional brain activity using regional homogeneity whereas the remaining studies all focused on seed-based functional connectivity indices. Zhang et al. [\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e] assessed seed-based connectivity of cholinergic basal forebrain nuclei whereas Querry et al. [\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e] and Wright et al. [\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e] assessed seed-based connectivity of multiple resting-state networks. While Xing et al.[\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e] found no significant associations between regional homogeneity values and either of their neuropsychiatric measures, Zhang et al. [\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e] found a significant positive correlation between HAMD scores and functional connectivity between the right nucleus basalis of Meynert and right middle cingulate and paracingulate gyri in PD-MCI. Wright et al. [\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e] also found significantly greater connectivity associated with both anxiety and affective disorder (depression and apathy), in PD-MCI, between the precuneus seed of the default mode network (DMN) and the subgenual cingulate, and between the orbitofrontal seed of the limbic network and areas of the DMN including the precuneus and subgenual cingulate. They also found affective disorder and anxiety severity to be associated with weaker connectivity between the limbic orbitofrontal seed and the brainstem and weaker connectivity between the salience network and the subgenual cingulate. No significant correlations were found between symptom severity and functional connectivity in the MCI-LB group, however. In DLB, however, the study by Querry et al. (2025) found significant positive correlations between MINI scores and functional connectivity between both the orbitofrontal cortex and inferior temporal gyrus and areas of the occipital lobe. Conversely, negative correlations were found between the MINI scores and functional connectivity between the inferior frontal cortex and occipital regions. The depressed DLB group were additionally found to have weaker connectivity between the cerebellum and lateral prefrontal cortex and greater connectivity between the lateral parietal cortex and the superior temporal gyrus, although these findings were only demonstrated at an uncorrected threshold.\u003c/p\u003e\u003cp\u003e\u003cem\u003eNeurotransmitter/Neurotransporter Studies\u003c/em\u003e\u003c/p\u003e\u003cp\u003eNeurotransmitter imaging studies were the most abundant studies included for review. None of the neurotransmitter studies included a cognitively impaired PD group. Three studies involving a total of 71 participants with DLB, 20 with prodromal DLB (MCI-LB) and 10 with AD, investigated dopamine transporter (DAT) striatal binding ratios using \u003csup\u003e123\u003c/sup\u003eI-FP-CIT single-photon emission computed tomography (SPECT) [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e, \u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e, \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e, \u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e] and a further two studies involving a total of 65 DLB patients investigated DAT binding ratios using either \u003csup\u003e18\u003c/sup\u003eF-FE-PE2I PET [\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e] or \u003csup\u003e18\u003c/sup\u003eF-FP-CIT PET [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e]. An additional single study of 11 participants with DLB and 12 HC investigated the density of vesicular acetylcholine transporter (VAchT) binding sites in several regions of interest within cholinergic pathways using \u003csup\u003e123\u003c/sup\u003eI-iodobenzovesamicol SPECT [\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e]. In five of the six studies, neuropsychiatric symptoms were correlated with DAT binding ratios. In one study, VAchT binding potentials were compared between apathetic and non-apathetic DLB patients. Four studies used the NPI to assess neuropsychiatric symptoms [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e, \u003cspan additionalcitationids=\"CR54\" citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e–\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e], one used the GDS to measure depression [\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e], and one used a questionnaire with 12 specific questions corresponding to the non-motor symptoms associated with LBD [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eIn three of the six studies, no associations were found between DAT binding and any neuropsychiatric symptoms [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e, \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e]. In the remaining studies, depression and apathy, as measured by the NPI, were found to be negatively correlated with DAT binding in the caudate [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e] anxiety was found to negatively correlate with DAT binding in the ventral striatum [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e], and VAchT binding potential values in the anterior cingulate were found to be significantly lower in DLB patients with apathy than without [\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e].\u003c/p\u003e\u003cp\u003e\u003cem\u003eOther Imaging Techniques\u003c/em\u003e\u003c/p\u003e\u003cp\u003eThe remaining studies utilized a range of different techniques to examine neuropsychiatric neural correlates in DLB and PD. A perfusion SPECT study examined regional cerebral blood flow in 95 DLB patients [\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e]. An \u003csup\u003e18\u003c/sup\u003eFDG-PET study examined glucose metabolism in patients with DLB (n = 28), AD (n = 741) and frontotemporal lobar degeneration (n = 137) [\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e]. An \u003csup\u003e18\u003c/sup\u003eF-florbetapir PET study examined regional Aβ deposition in 21 patients with PDD, 20 with AD and 9 HC [\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e] and a diffusion tensor imaging study examined free water values in the nucleus basalis of Meynert in 59 HC, 57 patients with idiopathic REM sleep behavior disorder, 57 patients with PD-NC, and 64 patients with PD-MCI using a 3T MRI scanner [\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThree of the four studies used correlational methods to determine the relationship between outcome measures and neuropsychiatric symptoms. The study by Murayama et al., [\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e] however, compared regional cerebral blood flow between DLB participants with and without depression. The studies used various methods to measure affective symptoms including the NPI, GDS and the State Trait Anxiety Inventory. Murayama et al.[\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e] did not explicitly state the specific neuropsychiatric measure used but implied that the presence of depression was determined as part of the clinical diagnostic protocol.\u003c/p\u003e\u003cp\u003eOf all the studies, only the study by Murayama et al. [\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e] found findings of significance. Free-water values, regional Aβ deposition and glucose metabolism were all found not to be associated with affective symptoms in either DLB, PDD or PD-MCI groups. Regional cerebral blood flow however was found to be greater in the angular gyrus and upper precuneus of DLB patients with depression than in those without.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis review aimed to elucidate the structural and functional neural correlates of affective symptoms in Lewy body dementias based on anatomical, functional, metabolic and neurotransmitter neuroimaging studies. The overwhelming take-away was the sheer paucity of research in this area. Given the limited data and few studies analyzing the relationship between affective symptoms and imaging metrics as a primary aim, imaging-based signatures of such symptoms in cognitively impaired LBD groups remain elusive and as such our aim to provide details regarding potential differences between disease stages and disease subtypes could only be partially met. Although a handful of studies reported some significant findings, there is little consensus within the currently available literature, highlighting a persisting need for further hypothesis driven research in larger, more diverse cohorts.\u003c/p\u003e\u003cp\u003eOf the eighteen studies included in the present review, only nine demonstrated a significant association between a given measure of anxiety, apathy or depression and brain structure or function. Most studies (17/18) included a measure of depression with far fewer investigating anxiety or apathy. As such, significant findings were predominantly limited to this symptom, with only two studies highlighting significant findings related to anxiety in cognitively impaired PD or DLB and only two highlighting a significant finding related to apathy in DLB.\u003c/p\u003e\u003cp\u003eIn cognitively impaired PD groups, only three studies identified significant neural correlates of affective symptom severity, two assessing functional connectivity and one assessing grey matter volume, all of which focused on PD-MCI. The study by Chang et al. [\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e] identified multiple regions of both higher and lower grey matter volume in several disparate brain regions among PD-MCI with depression when compared to those without. Although some previous studies have identified positive correlations between depression and volumetric or cortical thickness measures in PD [\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e, \u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e], such positive associations are at odds with a range of imaging research that has typically highlighted lower grey matter volume within limbic, prefrontal and insular regions, in depressed PD groups [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e]. Chang et al.’s study further highlighted a possible breakdown in structural covariance within the salience network in the depressed PD-MCI group compared with the non-depressed group. Such findings may align with functional connectivity analyses of major depressive disorder [\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e], and even PD-MCI [\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e], in which hypoconnectivity of the salience network has been found to relate to depression. However, the reliability of structural covariance metrics remains somewhat contentious [\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e] and as such, further research is needed to validate these findings.\u003c/p\u003e\u003cp\u003eFunctional imaging studies in cognitively impaired PD groups, however, appear to align more clearly with what has previously been established in cognitively healthy PD and broader models of psychopathology. In Wright et al.’s (2025) fMRI study, positive correlations between both ‘affective disorder’ and anxiety severity and functional connectivity were identified particularly between the limbic orbitofrontal cortex, subgenual cingulate, and regions of the DMN. Conversely, negative correlations were found between affective symptom severity and connectivity between the orbitofrontal cortex and the brainstem and between the subgenual cingulate and the salience network. In Zhang et al.’s [\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e] study, depression severity was additionally found to positively correlate with connectivity of the nucleus basalis of Meynert. Such findings by Wright et al. reflect those of previous research in cognitively healthy PD groups [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e, \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e], and literature from the broader psychiatric field, highlighting the significant involvement of the subgenual cingulate, limbic regions and imbalanced activity across the DMN and salience network in depression and anxiety disorders [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. This contributes towards a hypothesis that aberrant functional network connectivity may be a core underlying mechanism of neuropsychiatric symptoms in PD that is likely heavily influenced by LBD related changes in multiple neurotransmission pathways such as the serotonergic and dopaminergic systems [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. The findings by Zhang and colleagues further highlight a significant association between depression severity and connectivity between the cholinergic basal forebrain and cingulate cortex, a brain region frequently implicated in PD related affective symptoms [\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e, \u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e, \u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e, \u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e]. Earlier reviews of cholinergic deficits in PD have highlighted a potential connection between depression as a risk-factor for cognitive decline in PD and cholinergic dysfunction [\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e]. Given both early and recent discoveries suggesting an important role of the cholinergic system in mood regulation [\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e], and the increased cholinergic denervation associated with LBD cognitive decline [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e], this finding warrants further investigation as a possible mechanism underlying the observable relationship between cognitive decline and increasing affective symptom severity in LBDs [\u003cspan additionalcitationids=\"CR15 CR16 CR17 CR18\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e–\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eFar more studies, using a broader variety of techniques, examined affective symptoms in DLB. Of the 11 studies that included a DLB or MCI-LB group, six reported significant findings. Studies in DLB primarily utilized SPECT imaging to assess neurotransmission, with five investigating striatal DAT binding and one investigating the density of VAchT binding within cholinergic pathways. Conversely, none of the studies in cognitively impaired PD groups utilized such neurotransmission imaging techniques, possibly due to a wealth of research already providing evidence for a role of dopaminergic, serotonergic and noradrenergic denervation underlying affective symptoms in cognitively healthy PD [\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e]. In contrast with PD research that has shown significant correlations between anxiety, apathy and depression and DAT binding [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e, \u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e], evidence from DLB groups is sparse. Although two of the five DAT imaging studies identified some significant negative correlations between DAT binding in the striatum and either depression, apathy or anxiety in DLB ([\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e, \u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e], others reported a lack of significant association with any affective symptom [\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e, \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e, \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e]. Furthermore, Roselli et al. [\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e] demonstrated significant associations between depression and apathy and DAT binding within the caudate but found no association with anxiety. Conversely, Yoo et al. [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e] found only anxiety significantly correlated with DAT binding in the ventral striatum while apathy and depression were not associated with binding in any striatal region. Explanations for such discrepancies may lie in the substantial differences in study methodology, including imaging tracer and technique, diagnostic protocols, region of interest definition, and covariates in the analysis. Regardless, the directionality of results is consistent across both studies, with dopaminergic activity deficits within the striatum relating to manifestations of affective symptoms in DLB. Such findings are supported by neuropathological studies in DLB which have highlighted degeneration of dopaminergic pathways in depressed patients [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e], as well as neuroimaging studies in both cognitively healthy PD and other psychiatric and neurocognitive disorders [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan additionalcitationids=\"CR82\" citationid=\"CR81\" class=\"CitationRef\"\u003e81\u003c/span\u003e–\u003cspan citationid=\"CR83\" class=\"CitationRef\"\u003e83\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eAside from DAT-SPECT, Mazère et al.’s SPECT study [\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e], investigating VAchT, identified significantly lower VAchT binding within the anterior cingulate cortex in apathetic DLB patients compared with HC, despite no such difference being identified in non-apathetic DLB. Despite the limited sample size of this study, the results align with Zhang et al.’s findings [\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e] demonstrating a significant association between depression and functional connectivity deficits between the nucleus basalis of Meynert and cingulate cortex in PD-MCI, further highlighting the cholinergic system as an emerging area of interest regarding the pathophysiology of affective symptoms in cognitively impaired LBD.\u003c/p\u003e\u003cp\u003eOf the four functional imaging studies in DLB or MCI-LB, three reported significant findings. Interestingly, Murayama et al.’s study [\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e] identified significantly greater regional cerebral blood flow in areas corresponding to the DMN in depressed DLB participants, aligning with the DMN hyperconnectivity associated with affective disorder scores identified in PD-MCI by Wright et al.[\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e]. DMN regions were similarly highlighted by Querry et al.’s (2024) structural study in which depression was found to be negatively associated with grey matter volume within the middle frontal gyrus and precuneus. Such associations between depressive symptoms and DMN alterations are well established in the psychiatric literature and in previous studies in cognitively healthy PD [\u003cspan additionalcitationids=\"CR39\" citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e–\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. Overactivity of the DMN in relation to negative affective states has been hypothesized to result, in part, from dysfunctional dopaminergic circuits [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e], aligning with the denervation and pathological burden within dopaminergic pathways associated with depression in DLB [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e]. However, it must be noted in this case that such findings were not corroborated by Gan et al.’s \u003csup\u003e18\u003c/sup\u003eFDG-PET study [\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e] or either of the two fMRI studies in investigating DLB or MCI-LB [\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e, \u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e]. Rather, Querry et al.’s functional study [\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e] identified a range of both positive and negative associations between functional connectivity and depression in their DLB group that were largely located between the orbitofrontal and inferior temporal cortex and regions of the occipital lobe, with little to no involvement of regions associated with the DMN. Negative correlations were also identified between depression severity and within-network connectivity of the salience network. Although this may align with hypothesized contributions of salience network hypoconnectivity to negative affective states [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e], such findings were only identified at an uncorrected threshold and have yet to be replicated. At present, therefore, little corroboration exists within the literature regarding imaging correlates of affective symptoms in DLB.\u003c/p\u003e\u003cp\u003e\u003cem\u003eStrengths and Limitations\u003c/em\u003e\u003c/p\u003e\u003cp\u003eThe present review adhered to the PRISMA guidelines for systematic reviews, with a particular strength being the breadth of imaging techniques and symptom measures covered which captures the full spectrum of literature addressing the most common forms of affective symptoms in LBDs. A possible limitation, however, was the decision to exclude electrophysiological techniques, such as electroencephalography and magnetoencephalography, from both the search terms and through screening. The decision to exclude these techniques was made to limit the scope of this review to more easily comparable functional and structural outcome measures. However, such studies may prove beneficial in furthering our understanding of the neural mechanisms underlying affective symptoms in LBDs and as such their exclusion may be considered a limitation.\u003c/p\u003e\u003cp\u003eOne of the main limiting factors of the studies reviewed is that, except for DAT imaging, none of the imaging approaches utilized had been repeated within the same clinical subgroup across more than a single study, providing no opportunity to assess the replicability of the findings. Half of the studies did not identify any significant findings at all, resulting in little corroborating evidence across the literature. Furthermore, only half of the studies reviewed investigated the relationship between affective symptoms and neuroimaging metrics as a primary aim, meaning that not only were hypotheses not formulated around this specific research question, but many studies excluded participants based on the presence of clinically relevant psychiatric symptoms. Currently, therefore, it is hard to reconcile the multiple apparent inconsistencies across neuroimaging studies of affective symptoms in cognitively impaired LBD, given that the evidence base remains so limited. Furthermore, variations in imaging modalities, analysis techniques, neuropsychiatric measures and other confounding factors make the parsing out of valid and reliable findings from the idiosyncrasies of individual studies and disease cohorts significantly challenging.\u003c/p\u003e\u003cp\u003eA further limitation complicating the investigation of affective symptom neural correlates in Lewy body dementia is the known prevalence of mixed etiologies and co-morbid pathologies that may significantly impact clinical presentations [\u003cspan additionalcitationids=\"CR27\" citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e–\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan additionalcitationids=\"CR85\" citationid=\"CR84\" class=\"CitationRef\"\u003e84\u003c/span\u003e–\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e]. Of the studies included, only four included an Aβ biomarker and the vast majority of participants were diagnosed based solely on clinical criteria, limiting the possibility to determine pathology specific contributions to affective symptoms. In AD, tau and Aβ burden have not only been directly associated with affective symptoms [\u003cspan additionalcitationids=\"CR88\" citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e–\u003cspan citationid=\"CR89\" class=\"CitationRef\"\u003e89\u003c/span\u003e], but additionally impact specific neurotransmission systems, such as cholinergic pathways, that have an established role in affective symptom manifestation [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e, \u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e]. The study by Yoo et al.[\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e] further replicates the association between affective symptoms and AD pathology in DLB, finding that DLB participants with a high Aβ load demonstrated greater levels of anxiety and overall neuropsychiatric burden than Aβ-negative participants. Current imaging studies are therefore significantly limited by the relatively few well-characterized, pathologically confirmed study cohorts available, a limitation which may be significantly contributing towards the apparent lack of correspondence between some imaging studies and histopathological findings, particularly in DLB [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eFinally, it is well established within the psychiatric literature that symptoms such as depression, apathy and anxiety are not derived from a set of unitary diseases but rather each consist of a broad spectrum of features and characteristics that may be etiologically diverse across individuals [\u003cspan additionalcitationids=\"CR92\" citationid=\"CR91\" class=\"CitationRef\"\u003e91\u003c/span\u003e–\u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e93\u003c/span\u003e]. It is reasonable to predict, therefore, that the same is likely true of manifestations of affective symptoms in such complex and multifactorial conditions as Lewy body dementia, where a vast range of potential alterations within neurotransmission pathways and brain networks, resultant of either pure or mixed pathologies, may differentially contribute to symptom manifestation in each individual. Such diversity does not only arise from underlying pathology but is further complicated by the significant clinical overlaps not only between affective symptoms themselves but between affective symptoms and other clinical features of LBD such as motor deficits, sleep disturbance and cognitive fluctuations [\u003cspan additionalcitationids=\"CR95\" citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e–\u003cspan citationid=\"CR96\" class=\"CitationRef\"\u003e96\u003c/span\u003e]. A final substantial limitation of the current literature is therefore the use of a range of heterogeneous affective symptom rating scales, the validity of which have yet to be adequately assessed in the context of Lewy body dementia. The success of future clinical trials will, therefore, largely rely on research that is able to address such complications to establish meaningful neural correlates of symptom manifestations to provide therapeutic targets for symptomatic therapies.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThe findings of this review highlight a substantial gap in the literature that currently significantly limits our pathophysiological understanding of the well-established link between cognitive and neuropsychiatric decline in LBD. Such gaps in knowledge are a considerable hindrance to clinical trials seeking to develop effective interventions for these distressing and quality of life limiting symptoms. Future research should therefore focus on testing well-formulated hypotheses to replicate or extend the findings of earlier imaging studies, with the explicit aim of elucidating neural correlates of affective symptoms in cognitively impaired LBD groups. Optimizing symptom measurement and biomarker characterization of study cohorts may significantly improve future study protocols and consistency across the literature, therefore contributing towards a more robust theoretical basis for future therapeutic targets.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cspan lang=\"EN-GB\"\u003eCompeting Interests\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-GB\"\u003eThe authors have no competing interests to declare that are relevant to the content of this article.\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-GB\"\u003eFunding\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003eNM has no financial disclosures. LMW was supported by a bridging grant from ARUK (ARUK-ECRBF2023B-006) as well as being supported by the NIHR Newcastle Biomedical Research Centre.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-GB\"\u003eData availability\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003eThe data presented in this article may be provided by the authors upon reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-GB\"\u003eAuthors Contributions\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003e\u003cspan lang=\"EN-GB\"\u003eLMW conceptualised the design and protocol of the review and performed the literature search. Both NM and LMW conducted the screening, data extraction and quality assessment of studies. Both NM and LMW contributed to the writing and editing of the final manuscript.\u003c/span\u003e\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eAarsland D, Rongve A, Piepenstock Nore S, Skogseth R, Skulstad S, Ehrt U et al (2008) Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord 26(5):445\u0026ndash;452. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1159/000165917\u003c/span\u003e\u003cspan address=\"10.1159/000165917\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eEmre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22(12):1689\u0026ndash;1707. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.21507\u003c/span\u003e\u003cspan address=\"10.1002/mds.21507\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMcKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D et al (2017) Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89(1):88\u0026ndash;100. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1212/WNL.0000000000004058\u003c/span\u003e\u003cspan address=\"10.1212/WNL.0000000000004058\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBallard C, Aarsland D, Francis P, Corbett A (2013) Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. Drugs Aging 30(8):603\u0026ndash;611. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s40266-013-0092-x\u003c/span\u003e\u003cspan address=\"10.1007/s40266-013-0092-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288(12):1475\u0026ndash;1483. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1001/jama.288.12.1475\u003c/span\u003e\u003cspan address=\"10.1001/jama.288.12.1475\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDonaghy PC, Taylor JP, O'Brien JT, Barnett N, Olsen K, Colloby SJ et al (2018) Neuropsychiatric symptoms and cognitive profile in mild cognitive impairment with Lewy bodies. Psychol Med 48(14):2384\u0026ndash;2390. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1017/s0033291717003956\u003c/span\u003e\u003cspan address=\"10.1017/s0033291717003956\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBjoerke-Bertheussen J, Ehrt U, Rongve A, Ballard C, Aarsland D (2012) Neuropsychiatric symptoms in mild dementia with Lewy bodies and Alzheimer\u0026rsquo;s disease. Dement Geriatr Cogn Disord 34(1):1\u0026ndash;6. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1159/000339590\u003c/span\u003e\u003cspan address=\"10.1159/000339590\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDonaghy PC, Ciafone J, Durcan R, Hamilton CA, Barker S, Lloyd J et al (2022) Mild cognitive impairment with Lewy bodies: neuropsychiatric supportive symptoms and cognitive profile. Psychol Med 52(6):1147\u0026ndash;1155. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1017/S0033291720002901\u003c/span\u003e\u003cspan address=\"10.1017/S0033291720002901\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDissanayaka NN, Sellbach A, Silburn PA, O'Sullivan JD, Marsh R, Mellick GD (2011) Factors associated with depression in Parkinson's disease. J Affect Disord 132(1\u0026ndash;2):82\u0026ndash;88. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.jad.2011.01.021\u003c/span\u003e\u003cspan address=\"10.1016/j.jad.2011.01.021\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eEglit GM, Lopez F, Schiehser DM, Pirogovsky-Turk E, Litvan I, Lessig S et al (2021) Delineation of apathy subgroups in Parkinson's disease: differences in clinical presentation, functional ability, health‐related quality of life, and caregiver burden. Mov Disord Clin Pract 8(1):92\u0026ndash;99. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mdc3.13127\u003c/span\u003e\u003cspan address=\"10.1002/mdc3.13127\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHeimrich KG, Sch\u0026ouml;nenberg A, Mendorf S, Moussaoui J, Prell T (2024) An examination of anxiety and its influence on health-related quality of life in Parkinson\u0026rsquo;s disease using the geriatric anxiety scale: a cross-sectional study. BMC Geriatr 24(1):298. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12877-024-04911-8\u003c/span\u003e\u003cspan address=\"10.1186/s12877-024-04911-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKuhlman GD, Flanigan JL, Sperling SA, Barrett MJ (2019) Predictors of health-related quality of life in Parkinson's disease. Parkinsonism Relat Disord 65:86\u0026ndash;90. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.parkreldis.2019.05.009\u003c/span\u003e\u003cspan address=\"10.1016/j.parkreldis.2019.05.009\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVan de Beek M, van Steenoven I, van der Zande J, Porcelijn I, Barkhof F, Stam C et al (2021) Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. Alzheimers Res Ther 13(1):53. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s13195-021-00792-w\u003c/span\u003e\u003cspan address=\"10.1186/s13195-021-00792-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBreitve MH, Br\u0026oslash;nnick K, Chwiszczuk LJ, Hynninen MJ, Aarsland D, Rongve A (2018) Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. Alzheimers Res Ther 10(1):83. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s13195-018-0416-5\u003c/span\u003e\u003cspan address=\"10.1186/s13195-018-0416-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBreitve MH, Hynninen MJ, Br\u0026oslash;nnick K, Chwiszczuk LJ, Auestad BH, Aarsland D et al (2016) A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer\u0026rsquo;s disease. Alzheimers Res Ther 8(1):3. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s13195-016-0171-4\u003c/span\u003e\u003cspan address=\"10.1186/s13195-016-0171-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDissanayaka NN, Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK et al (2017) Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. Parkinsonism Relat Disord 36:63\u0026ndash;68. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.parkreldis.2017.01.001\u003c/span\u003e\u003cspan address=\"10.1016/j.parkreldis.2017.01.001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWyman-Chick KA, O\u0026rsquo;Keefe LR, Weintraub D, Armstrong MJ, Rosenbloom M, Martin PK et al (2022) Prodromal dementia with Lewy bodies: evolution of symptoms and predictors of dementia onset. J Geriatr Psychiatry Neurol 35(4):527\u0026ndash;534. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1177/08919887211023586\u003c/span\u003e\u003cspan address=\"10.1177/08919887211023586\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDujardin K, Sockeel P, Delliaux M, Dest\u0026eacute;e A, Defebvre L (2009) Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord 24(16):2391\u0026ndash;2397. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.22843\u003c/span\u003e\u003cspan address=\"10.1002/mds.22843\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJones JD, Kurniadi NE, Kuhn TP, Szymkowicz SM, Bunch J, Rahmani E (2019) Depressive symptoms precede cognitive impairment in de novo Parkinson\u0026rsquo;s disease patients: Analysis of the PPMI cohort. Neuropsychology 33(8):1111. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1037/neu0000583\u003c/span\u003e\u003cspan address=\"10.1037/neu0000583\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDen Brok MG, van Dalen JW, van Gool WA, van Moll EP, de Bie RM, Richard E (2015) Apathy in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 30(6):759\u0026ndash;769. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.26208\u003c/span\u003e\u003cspan address=\"10.1002/mds.26208\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDissanayaka NN, Sellbach A, Matheson S, O'Sullivan JD, Silburn PA, Byrne GJ et al (2010) Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 25(7):838\u0026ndash;845. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.22833\u003c/span\u003e\u003cspan address=\"10.1002/mds.22833\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLee DR, McKeith I, Mosimann U, Ghosh-Nodyal A, Thomas AJ (2013) Examining carer stress in dementia: the role of subtype diagnosis and neuropsychiatric symptoms. Int J Geriatr Psychiatry 28(2):135\u0026ndash;141. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/gps.3799\u003c/span\u003e\u003cspan address=\"10.1002/gps.3799\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLiu S, Liu J, Wang X-D, Shi Z, Zhou Y, Li J et al (2018) Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer's disease. Int Psychogeriatr 30(8):1131\u0026ndash;1138. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1017/S1041610217002630\u003c/span\u003e\u003cspan address=\"10.1017/S1041610217002630\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAlzahrani H, Venneri A (2015) Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: A systematic review. J Neurol Sci 356(1\u0026ndash;2):32\u0026ndash;44. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.jns.2015.06.037\u003c/span\u003e\u003cspan address=\"10.1016/j.jns.2015.06.037\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWen MC, Chan LL, Tan LC, Tan EK (2016) Depression, anxiety, and apathy in Parkinson's disease: insights from neuroimaging studies. Eur J Neurol 23(6):1001\u0026ndash;1019. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/ene.13002\u003c/span\u003e\u003cspan address=\"10.1111/ene.13002\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eIrwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX et al (2017) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 16(1):55\u0026ndash;65. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/S1474-4422(16)30291-5\u003c/span\u003e\u003cspan address=\"10.1016/S1474-4422(16)30291-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eOkkels N, Grothe MJ, Taylor J-P, Hasselbalch SG, Fedorova TD, Knudsen K et al (2024) Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes. Brain 147(7):2308\u0026ndash;2324. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/brain/awae069\u003c/span\u003e\u003cspan address=\"10.1093/brain/awae069\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eIrwin DJ, Hurtig HI (2018) The contribution of tau, amyloid-beta and alpha-synuclein pathology to dementia in Lewy body disorders. J Alzheimers Dis Parkinsonism 8(4):444. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.4172/2161-0460.1000444\u003c/span\u003e\u003cspan address=\"10.4172/2161-0460.1000444\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCarey G, G\u0026ouml;rmezoğlu M, de Jong JJ, Hofman PA, Backes WH, Dujardin K et al (2021) Neuroimaging of anxiety in Parkinson's disease: a systematic review. Mov Disord 36(2):327\u0026ndash;339. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.28404\u003c/span\u003e\u003cspan address=\"10.1002/mds.28404\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSharp SI, Ballard CG, Ziabreva I, Piggott MA, Perry RH, Perry EK et al (2008) Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson\u0026rsquo;s disease dementia. Dement Geriatr Cogn 26(4):330\u0026ndash;338. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1159/000161058\u003c/span\u003e\u003cspan address=\"10.1159/000161058\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePatterson L, Rushton SP, Attems J, Thomas AJ, Morris CM (2019) Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders. Brain Pathol 29(4):544\u0026ndash;557. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/bpa.12697\u003c/span\u003e\u003cspan address=\"10.1111/bpa.12697\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRoselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF et al (2009) Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP‐CIT SPECT study. Mov Disord 24(14):2097\u0026ndash;2103. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.22702\u003c/span\u003e\u003cspan address=\"10.1002/mds.22702\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFischer NM, Hinkle JT, Perepezko K, Bakker CC, Morris M, Broen MP et al (2021) Brainstem pathologies correlate with depression and psychosis in Parkinson's disease. Am J Geriatr Psychiatry 29(9):958\u0026ndash;968. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.jagp.2020.12.009\u003c/span\u003e\u003cspan address=\"10.1016/j.jagp.2020.12.009\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBohnen N, Kaufer D, Hendrickson R, Constantine G, Mathis C, Moore R (2007) Cortical cholinergic denervation is associated with depressive symptoms in Parkinson\u0026rsquo;s disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry 78(6):641\u0026ndash;643. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.bbr.2009.12.048\u003c/span\u003e\u003cspan address=\"10.1016/j.bbr.2009.12.048\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRemy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(6):1314\u0026ndash;1322. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/brain/awh445\u003c/span\u003e\u003cspan address=\"10.1093/brain/awh445\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMaillet A, Krack P, Lhomm\u0026eacute;e E, M\u0026eacute;t\u0026eacute;reau E, Klinger H, Favre E et al (2016) The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson\u0026rsquo;s disease. Brain 139(9):2486\u0026ndash;2502. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/brain/aww162\u003c/span\u003e\u003cspan address=\"10.1093/brain/aww162\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eConio B, Martino M, Magioncalda P, Escelsior A, Inglese M, Amore M et al (2020) Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders. Mol Psychiatry 25(1):82\u0026ndash;93. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41380-019-0406-4\u003c/span\u003e\u003cspan address=\"10.1038/s41380-019-0406-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDrevets WC, Savitz J, Trimble M (2008) The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 13(8):663. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1017/s1092852900013754\u003c/span\u003e\u003cspan address=\"10.1017/s1092852900013754\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHu X, Song X, Li E, Liu J, Yuan Y, Liu W et al (2015) Altered resting-state brain activity and connectivity in depressed Parkinson\u0026rsquo;s disease. PLoS ONE 10(7):e0131133. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1371/journal.pone.0131133\u003c/span\u003e\u003cspan address=\"10.1371/journal.pone.0131133\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDan R, Růžička F, Bezdicek O, Růžička E, Roth J, Vymazal J et al (2017) Separate neural representations of depression, anxiety and apathy in Parkinson\u0026rsquo;s disease. Sci Rep 7(1):12164. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41598-017-12457-6\u003c/span\u003e\u003cspan address=\"10.1038/s41598-017-12457-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGliaudelytė L, Rushton SP, Berlinguer-Palmini R, Thomas AJ, Morris CM (2025) Dopaminergic changes in the subgenual cingulate cortex in dementia with lewy bodies associates with presence of depression. Transl Psychiatry 15(1):89. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41398-025-03298-3\u003c/span\u003e\u003cspan address=\"10.1038/s41398-025-03298-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePagonabarraga J, Kulisevsky J, Strafella AP, Krack P (2015) Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 14(5):518\u0026ndash;531. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/S1474-4422(15)00019-8\u003c/span\u003e\u003cspan address=\"10.1016/S1474-4422(15)00019-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJellinger KA, Korczyn AD (2018) Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? BMC Med 16(1):34. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12916-018-1016-8\u003c/span\u003e\u003cspan address=\"10.1186/s12916-018-1016-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWeintraub D (2023) What's in a name? The time has come to unify Parkinson's disease and dementia with Lewy bodies. Mov Disord 38(11):1977\u0026ndash;1981. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.29590\u003c/span\u003e\u003cspan address=\"10.1002/mds.29590\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePower JH, Barnes OL, Chegini F (2017) L ewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson's Disease and Dementia with Lewy Bodies. Brain Pathol 27(1):3\u0026ndash;12. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/bpa.12344\u003c/span\u003e\u003cspan address=\"10.1111/bpa.12344\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSpillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u0026rsquo;s disease and dementia with Lewy bodies. Proc Natl Acad Sci 95(11):6469\u0026ndash;6473. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1073/pnas.95.11.6469\u003c/span\u003e\u003cspan address=\"10.1073/pnas.95.11.6469\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePostuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30(12):1591\u0026ndash;1601. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.26424\u003c/span\u003e\u003cspan address=\"10.1002/mds.26424\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLitvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 27(3):349\u0026ndash;356. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.24893\u003c/span\u003e\u003cspan address=\"10.1002/mds.24893\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMcKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H et al (2020) Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 94(17):743\u0026ndash;755. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1212/WNL.0000000000009323\u003c/span\u003e\u003cspan address=\"10.1212/WNL.0000000000009323\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGoldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE (2014) The spectrum of cognitive impairment in Lewy body diseases. Mov Disord 29(5):608\u0026ndash;621. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.25866\u003c/span\u003e\u003cspan address=\"10.1002/mds.25866\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePage MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1136/bmj.n71\u003c/span\u003e\u003cspan address=\"10.1136/bmj.n71\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKasanuki K, Iseki E, Ota K, Kondo D, Ichimiya Y, Sato K, Arai H (2017) 123I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 44(3):358\u0026ndash;365. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s00259-016-3466-6\u003c/span\u003e\u003cspan address=\"10.1007/s00259-016-3466-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMaz\u0026egrave;re J, Lamare F, Allard M, Fernandez P, Mayo W (2017) 123I-Iodobenzovesamicol SPECT Imaging of Cholinergic Systems in Dementia with Lewy Bodies. J Nucl Med 58(1):123\u0026ndash;128. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2967/jnumed.116.176180\u003c/span\u003e\u003cspan address=\"10.2967/jnumed.116.176180\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSiepel F, Dalen I, Gr\u0026uuml;ner R, Booij J, Br\u0026oslash;nnick K, Buter T et al (2016) Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies. Mov Disord 31(1):118\u0026ndash;125. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.26327\u003c/span\u003e\u003cspan address=\"10.1002/mds.26327\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYoo H, Lee S, Chung S, Lee Y, Ye B, Sohn Y et al (2020) Clinical and striatal dopamine transporter predictors of β-amyloid in dementia with Lewy bodies. Neurology 94(13):e1344\u0026ndash;e52. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1212/WNL.0000000000009168\u003c/span\u003e\u003cspan address=\"10.1212/WNL.0000000000009168\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSturchio A, Svensson JE, Tiger M, Mor\u0026eacute;n AF, Varrone A, Svenningsson P et al (2025) [18F] FE-PE2I PET is a diagnostic tool in dementia with Lewy bodies. PCN Rep 4(2):e70123. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/pcn5.70123\u003c/span\u003e\u003cspan address=\"10.1002/pcn5.70123\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAlmeida O, Burton E, McKeith I, Gholkar A, Burn D, O'Brien J (2003) MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 16(2):57\u0026ndash;63. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1159/000070676\u003c/span\u003e\u003cspan address=\"10.1159/000070676\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChang Y, Lu C, Wu M, Hsu S, Huang C, Chang W et al (2017) Salience Network and Depressive Severities in Parkinson's Disease with Mild Cognitive Impairment: A Structural Covariance Network Analysis. Front Aging Neurosc 9:417. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fnagi.2017.00417\u003c/span\u003e\u003cspan address=\"10.3389/fnagi.2017.00417\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJaramillo-Jimenez A, Giil L, Tovar-Rios D, Borda M, Ferreira D, Br\u0026oslash;nnick K et al (2021) Association Between Amygdala Volume and Trajectories of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia With Lewy Bodies. Front Neurol 12:679984. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fneur.2021.679984\u003c/span\u003e\u003cspan address=\"10.3389/fneur.2021.679984\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eQuerry M, Botzung A, Cretin B, Demuynck C, Muller C, Ravier A et al Neuroanatomical substrates of depression in dementia with Lewy bodies and Alzheimer\u0026rsquo;s disease. GeroScience. 2024:1\u0026ndash;20. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s11357-024-01190-4\u003c/span\u003e\u003cspan address=\"10.1007/s11357-024-01190-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eXing Y, Fu S, Li M, Ma X, Liu M, Liu X et al (2021) Regional neural activity changes in Parkinson's disease-associated mild cognitive impairment and cognitively normal patients. Neuropsychiatr Dis Treat 17. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2147/NDT.S323127\u003c/span\u003e\u003cspan address=\"10.2147/NDT.S323127\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhang P, Rong S, He C, Li Y, Li X, Chen Z et al (2023) Cortical connectivity of cholinergic basal forebrain in Parkinson's disease with mild cognitive impairment. Quant Imaging Med Surg 13(4):2167\u0026ndash;2182. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.21037/qims-22-582\u003c/span\u003e\u003cspan address=\"10.21037/qims-22-582\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eQuerry M, Botzung A, Sourty M, Chabran E, Sanna L, Loureiro de Sousa P et al (2025) Functional Connectivity Changes Associated With Depression in Dementia With Lewy Bodies. Int J Geriatr Psychiatry 40(3):e70058. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/gps.70058\u003c/span\u003e\u003cspan address=\"10.1002/gps.70058\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWright LM, Donaghy PC, Burn DJ, Taylor J-P, T O\u0026rsquo;Brien J, Yarnall AJ et al (2025) Brain network connectivity underlying neuropsychiatric symptoms in prodromal Lewy body dementia. Neurobiol Aging. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.neurobiolaging.2025.04.007\u003c/span\u003e\u003cspan address=\"10.1016/j.neurobiolaging.2025.04.007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGan J, Shi Z, Zuo C, Zhao X, Liu S, Chen Y et al (2023) Analysis of positron emission tomography hypometabolic patterns and neuropsychiatric symptoms in patients with dementia syndromes. CNS Neurosci Ther 29(8):2193\u0026ndash;2205. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/cns.14169\u003c/span\u003e\u003cspan address=\"10.1111/cns.14169\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMurayama T, Kobayashi S, Ishida T, Utsumi K, Kawanishi C (2022) Associations Between Regional Cerebral Blood Flow and Psychiatric Symptoms in Dementia With Lewy Bodies Without Parkinsonism. Am J Alzheimers Dis Other Deme 37:15333175221075109. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1177/15333175221075109\u003c/span\u003e\u003cspan address=\"10.1177/15333175221075109\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePalermo G, Tommasini L, Aghakhanyan G, Frosini D, Giuntini M, Tognoni G et al (2019) Clinical correlates of cerebral amyloid deposition in Parkinson's disease dementia: Evidence from a PET study. J Alzheimers Dis 70(2):597\u0026ndash;609. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://dx.doi.org/10.3233/JAD-190323\u003c/span\u003e\u003cspan address=\"10.3233/JAD-190323\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhang D, Zhou L, Lu C, Feng T, Liu J, Wu T (2024) Free-Water Imaging of the Nucleus Basalis of Meynert in Patients With Idiopathic REM Sleep Behavior Disorder and Parkinson Disease. Neurology 102(7):e209220. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1212/WNL.0000000000209220\u003c/span\u003e\u003cspan address=\"10.1212/WNL.0000000000209220\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12):2308. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1212/wnl.44.12.2308\u003c/span\u003e\u003cspan address=\"10.1212/wnl.44.12.2308\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003evan Mierlo TJ, Chung C, Foncke EM, Berendse HW, van den Heuvel OA (2015) Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume. Mov Disord 30(2):245\u0026ndash;252. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.26112\u003c/span\u003e\u003cspan address=\"10.1002/mds.26112\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZanigni S, Sambati L, Evangelisti S, Testa C, Calandra-Buonaura G, Manners DN et al (2017) Precuneal thickness and depression in Parkinson disease. Neurodegener Dis 17(2\u0026ndash;3):97\u0026ndash;102. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1159/000450614\u003c/span\u003e\u003cspan address=\"10.1159/000450614\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJellinger KA (2022) The pathobiological basis of depression in Parkinson disease: challenges and outlooks. J Neural Transm 129(12):1397\u0026ndash;1418. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s00702-022-02559-5\u003c/span\u003e\u003cspan address=\"10.1007/s00702-022-02559-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA (2015) Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. JAMA Psychiatry 72(6):603\u0026ndash;611. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1001/jamapsychiatry.2015.0071\u003c/span\u003e\u003cspan address=\"10.1001/jamapsychiatry.2015.0071\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCarmon J, Heege J, Necus JH, Owen TW, Pipa G, Kaiser M et al (2020) Reliability and comparability of human brain structural covariance networks. NeuroImage 220:117104. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.neuroimage.2020.117104\u003c/span\u003e\u003cspan address=\"10.1016/j.neuroimage.2020.117104\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLou Y, Huang P, Li D, Cen Z, Wang B, Gao J et al (2015) Altered brain network centrality in depressed Parkinson's disease patients. Mov Disord 30(13):1777\u0026ndash;1784. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.26321\u003c/span\u003e\u003cspan address=\"10.1002/mds.26321\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWei L, Hu X, Zhu Y, Yuan Y, Liu W, Chen H (2017) Aberrant intra-and internetwork functional connectivity in depressed Parkinson\u0026rsquo;s disease. Sci Rep 7(1):2568. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41598-017-02127-y\u003c/span\u003e\u003cspan address=\"10.1038/s41598-017-02127-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBohnen NI, Albin RL (2011) The cholinergic system and Parkinson disease. Behav Brain Res 221(2):564\u0026ndash;573. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1136/jnnp.2006.100073\u003c/span\u003e\u003cspan address=\"10.1136/jnnp.2006.100073\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDulawa SC, Janowsky DS (2019) Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. Mol Psychiatry 24(5):694\u0026ndash;709. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41380-018-0219-x\u003c/span\u003e\u003cspan address=\"10.1038/s41380-018-0219-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePrange S, Klinger H, Laurencin C, Danaila T, Thobois S (2022) Depression in patients with Parkinson\u0026rsquo;s disease: current understanding of its neurobiology and implications for treatment. Drugs Aging 39(6):417\u0026ndash;439. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s40266-022-00942-1\u003c/span\u003e\u003cspan address=\"10.1007/s40266-022-00942-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRektorova I, Biundo R, Marecek R, Weis L, Aarsland D, Antonini A (2014) Grey matter changes in cognitively impaired Parkinson's disease patients. PLoS ONE 9(1):e85595. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1371/journal.pone.0085595\u003c/span\u003e\u003cspan address=\"10.1371/journal.pone.0085595\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64(3):327\u0026ndash;337. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1001/archpsyc.64.3.327\u003c/span\u003e\u003cspan address=\"10.1001/archpsyc.64.3.327\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLe Heron C, Apps M, Husain M (2018) The anatomy of apathy: a neurocognitive framework for amotivated behaviour. Neuropsychologia 118:54\u0026ndash;67. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.neuropsychologia.2017.07.003\u003c/span\u003e\u003cspan address=\"10.1016/j.neuropsychologia.2017.07.003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eUdo N, Hashimoto N, Toyonaga T, Isoyama T, Oyanagi Y, Narita H et al (2020) Apathy in Alzheimer\u0026rsquo;s disease correlates with the dopamine transporter level in the caudate nuclei. Dement Geriatr Cogn Dis Extra 10(2):86\u0026ndash;93. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1159/000509278\u003c/span\u003e\u003cspan address=\"10.1159/000509278\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChatterjee A, Hirsch-Reinshagen V, Moussavi SA, Ducharme B, Mackenzie IR, Hsiung GYR (2021) Clinico‐pathological comparison of patients with autopsy‐confirmed Alzheimer's disease, dementia with Lewy bodies, and mixed pathology. Alzheimer's Dement: Diagn Assess Dis Monit 13(1):e12189. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/dad2.12189\u003c/span\u003e\u003cspan address=\"10.1002/dad2.12189\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJellinger KA, Attems J (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115(4):427\u0026ndash;436. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s00401-008-0347-5\u003c/span\u003e\u003cspan address=\"10.1007/s00401-008-0347-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMerdes A, Hansen L, Jeste D, Galasko D, Hofstetter C, Ho G et al (2003) Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60(10):1586\u0026ndash;1590. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1212/01.wnl.0000065889.42856.f2\u003c/span\u003e\u003cspan address=\"10.1212/01.wnl.0000065889.42856.f2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBabulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TL et al (2016) Mood changes in cognitively normal older adults are linked to Alzheimer disease biomarker levels. \u003cem\u003eAm J Geriatr Psychiatry\u003c/em\u003e. ;24(11):1095\u0026thinsp;\u0026ndash;\u0026thinsp;104. https://doi.org/1095-1104.10.1016/j.jagp.2016.04.004\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKrell-Roesch J, Rakusa M, Syrjanen JA, van Harten AC, Lowe VJ, Jack CR Jr et al (2023) Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. Alzheimers Dement 19(10):4498\u0026ndash;4506. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/alz.12557\u003c/span\u003e\u003cspan address=\"10.1002/alz.12557\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYasuno F, Minami H, Hattori H, Initiative ADN (2021) Relationship between neuropsychiatric symptoms and Alzheimer's disease pathology: An in vivo positron emission tomography study. Int J Geriatr Psychiatry 36(4):598\u0026ndash;605. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/gps.5459\u003c/span\u003e\u003cspan address=\"10.1002/gps.5459\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHampel H, Mesulam M-M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer\u0026rsquo;s disease. Brain 141(7):1917\u0026ndash;1933. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/brain/awy132\u003c/span\u003e\u003cspan address=\"10.1093/brain/awy132\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBuch AM, Liston C (2021) Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics. Neuropsychopharmacology 46(1):156\u0026ndash;. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41386-020-00789-3\u003c/span\u003e\u003cspan address=\"10.1038/s41386-020-00789-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. \u0026thinsp;75\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLevy R, Dubois B (2006) Apathy and the functional anatomy of the prefrontal cortex\u0026ndash;basal ganglia circuits. Cereb Cortex 16(7):916\u0026ndash;928. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/cercor/bhj043\u003c/span\u003e\u003cspan address=\"10.1093/cercor/bhj043\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAkiki TJ, Jubeir J, Bertrand C, Tozzi L, Williams LM (2025) Neural circuit basis of pathological anxiety. Nat Rev Neurosci 26(1):5\u0026ndash;22. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41583-024-00880-4\u003c/span\u003e\u003cspan address=\"10.1038/s41583-024-00880-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBurn DJ, Landau S, Hindle JV, Samuel M, Wilson KC, Hurt CS et al (2012) Parkinson's disease motor subtypes and mood. Mov Disord 27(3):379\u0026ndash;386. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/mds.24041\u003c/span\u003e\u003cspan address=\"10.1002/mds.24041\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eElder GJ, Colloby SJ, Lett DJ, O'Brien JT, Anderson KN, Burn DJ et al (2016) Depressive symptoms are associated with daytime sleepiness and subjective sleep quality in dementia with Lewy bodies. Int J Geriatr Psychiatry 31(7):765\u0026ndash;770. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/gps.4389\u003c/span\u003e\u003cspan address=\"10.1002/gps.4389\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTherrien S, Turnbull A, Anthony M, Conwell Y, Lin FV (2023) Influence of affective states on informant impression of neuropsychiatric symptoms in people living with MCI. Aging Ment Health 27(11):2128\u0026ndash;2133. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1080/13607863.2023.2191928\u003c/span\u003e\u003cspan address=\"10.1080/13607863.2023.2191928\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTables not available with this version.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Newcastle University","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":true,"isPdf":false,"isPdfUpToDate":true,"journal":{"display":true,"email":"info@researchsquare.com","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Lewy body dementia, affective symptoms, neuroimaging, apathy, depression, anxiety","lastPublishedDoi":"10.21203/rs.3.rs-7472898/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7472898/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e\u003cp\u003eAffective symptoms, such as depression, anxiety and apathy, are highly prevalent in Lewy body diseases (LBDs), including both Parkinson\u0026rsquo;s disease and dementia with Lewy bodies. Despite their association with cognitive decline, their underlying neuropathological mechanisms, in the context of cognitive impairment, remain poorly understood. This systematic review examines the neural correlates of affective symptoms in cognitively impaired LBD based on anatomical, functional, metabolic and neurotransmitter imaging studies.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e\u003cp\u003eLiterature searches conducted using PubMed, PsychINFO and Web of Science, identified eighteen eligible studies, including 785 participants, that included assessments of depression, anxiety or apathy; an acceptable method of neuroimaging; and participants with a diagnosis of LBD and evidence of cognitive impairment. A narrative synthesis of their findings is provided.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003eSignificant heterogeneity in imaging techniques, study protocols and cohort characteristics were identified. Half of the studies did not report significant findings, and only dopaminergic imaging was used by more than one study within the same clinical subgroup. Some evidence highlights involvement of intrinsic brain networks, such as the default mode and salience networks, in affective symptom manifestation. Additionally, two studies found associations between affective symptoms and cholinergic denervation, providing a potential neuropathological connection between neuropsychiatric and cognitive decline in LBD.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e\u003cp\u003eThe paucity of studies, and heterogeneity within them, significantly hinder the development of robust hypotheses regarding the neuropathology of affective symptoms in LBD cognitive impairment. This review therefore emphasises the need for more targeted research to understand these underlying mechanisms to inform future therapeutic strategies.\u003c/p\u003e","manuscriptTitle":"Neuroimaging of affective symptoms in Lewy body dementia: A systematic review","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-09-01 10:33:17","doi":"10.21203/rs.3.rs-7472898/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"info@researchsquare.com","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"86950e1a-9d12-453f-a3d4-40646439c65a","owner":[],"postedDate":"September 1st, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":53795258,"name":"Neurology"},{"id":53795259,"name":"Psychiatry"}],"tags":[],"updatedAt":"2025-09-01T10:33:17+00:00","versionOfRecord":[],"versionCreatedAt":"2025-09-01 10:33:17","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7472898","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"identity":"rs-7472898","version":["v1"]},"buildId":"pX42vdylg-PjXqQvD3Sgd","isFallback":false,"dynamicIds":[87228],"gssp":true,"scriptLoader":[]}</script><div hidden="" id="snipcart" data-api-key="ODA3NTlmNDUtYjRjNy00MzE2LTgzNmYtYjUwY2Y4MWFkOWRlNjM3MTQwMjI1MDM0NDU2MjEx"></div></body></html>